{"content":"<li class=\"n-box-item date-title\" data-end=\"1538452799\" data-start=\"1538366400\" data-txt=\"Monday, December 23, 2019\">Monday, October  1, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3394285\" data-ts=\"1538433826\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SEAS\" target=\"_blank\">SEAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394285-seaworldplus-6-after-reporting-revenue-rose-9-attendanceplus-10-in-q3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SeaWorld +6% after reporting revenue rose 9%, attendance +10% in Q3</a></h4><ul>     <li>SeaWorld Entertainment (NYSE:<a href='https://seekingalpha.com/symbol/SEAS' title='SeaWorld Entertainment Inc.'>SEAS</a>)&nbsp;<font color='green'>+6.7%</font> after-hours as it reports <a href=\"https://seekingalpha.com/pr/17287039-seaworld-entertainment-inc-reports-attendance-preliminary-revenue-september-30-2018\" target=\"_blank\">preliminary Q3 revenue growth of ~9% Y/Y</a>, or $41M, well ahead of the analyst consensus of 5.6% growth.</li>     <li>SEAS also says attendance figures jumped 10% Y/Y for the three-month period ended Sept. 30; YTD, total attendance has increased 9%, or ~1.4M guests, and revenues rose 9%, or $90M.</li><li>The report is required under a potential deal SEAS made to refinance debt.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3394285\" data-linked=\"SeaWorld +6% after reporting revenue rose 9%, attendance +10% in Q3\" data-tweet=\"$SEAS - SeaWorld +6% after reporting revenue rose 9%, attendance +10% in Q3 https://seekingalpha.com/news/3394285-seaworldplus-6-after-reporting-revenue-rose-9-attendanceplus-10-in-q3?source=tweet\" data-url=\"https://seekingalpha.com/news/3394285-seaworldplus-6-after-reporting-revenue-rose-9-attendanceplus-10-in-q3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:43 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394283\" data-ts=\"1538431859\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PZZA\" target=\"_blank\">PZZA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394283-papa-johnsplus-4_3-legion-says-may-engage-in-talks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Papa John&#39;s +4.3% as Legion says it may engage in talks</a></h4><ul>   <li>In an <a href=\"https://seekingalpha.com/filing/4186375\" target=\"_blank\">SEC disclosure</a>, Legion Partners says it may engage in talks with the board at Papa John's (NASDAQ:<a href='https://seekingalpha.com/symbol/PZZA' title='Papa John&#39;s International, Inc.'>PZZA</a>).</li>    <li>Shares of the pizza maker are <font color='green'>up 4.3%</font> after hours.</li>    <li>Legion is a holder of 5.46% of the company.</li>    <li>It says it may look for communications with management, the board and shareholders about issues including changing capitalization, ownership structure, makeup of the board and other topics.</li>    <li>Legion believes \"the current market price does not reflect the Issuer's intrinsic value\" and says it's encouraged by actions to move past recent controversies, saying \"multiple potential paths to significantly higher valuations exist for the issuer through strategic partnerships or improving operations as a stand-alone company.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3394283\" data-linked=\"Papa John&#39;s +4.3% as Legion says it may engage in talks\" data-tweet=\"$PZZA - Papa John&#39;s +4.3% as Legion says it may engage in talks https://seekingalpha.com/news/3394283-papa-johnsplus-4_3-legion-says-may-engage-in-talks?source=tweet\" data-url=\"https://seekingalpha.com/news/3394283-papa-johnsplus-4_3-legion-says-may-engage-in-talks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394276\" data-ts=\"1538429704\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IGC\" target=\"_blank\">IGC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394276-after-hours-gainers-losers-10-01-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (10/01/2018)</a></h4><ul><li><b>Top Gainers:</b>&nbsp;<a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a>&nbsp;<font color='green'>+11.4%</font>. <a href='https://seekingalpha.com/symbol/OMER' title='Omeros Corporation'>OMER</a> <font color='green'>+9.9%</font>. <a href='https://seekingalpha.com/symbol/DTEA' title='DAVIDs TEA'>DTEA</a> <font color='green'>+9.4%</font>. <a href='https://seekingalpha.com/symbol/SENS' title='Senseonics Holdings'>SENS</a> <font color='green'>+4.6%</font>. <a href='https://seekingalpha.com/symbol/SYN' title='Synthetic Biologics, Inc.'>SYN</a>&nbsp;<font color='green'>+3.9%</font>.</li><li><b>Top Losers:</b> <a href='https://seekingalpha.com/symbol/SFIX' title='Stitch Fix, Inc.'>SFIX</a> <font color='red'>-20.7%</font>. <a href='https://seekingalpha.com/symbol/CLSK' title='Cleanspark, Inc.'>OTCQB:CLSK</a> <font color='red'>-6.8%</font>. <a href='https://seekingalpha.com/symbol/CHI' title='Calamos Convertible Opportunities&Income Fund'>CHI</a>&nbsp;<font color='red'>-2.3%.</font>&nbsp;<a href='https://seekingalpha.com/symbol/AOBC' title='American Outdoor Brands Corporation'>AOBC</a> <font color='red'>-1.8%</font>. <a href='https://seekingalpha.com/symbol/GWPH' title='GW Pharmaceuticals plc'>GWPH</a> <font color='red'>-1.5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3394276\" data-linked=\"After Hours Gainers / Losers (10/01/2018)\" data-tweet=\"$IGC $IGC $OMER - After Hours Gainers / Losers (10/01/2018) https://seekingalpha.com/news/3394276-after-hours-gainers-losers-10-01-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3394276-after-hours-gainers-losers-10-01-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394274\" data-ts=\"1538429376\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SMSI\" target=\"_blank\">SMSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394274-smith-micro-closesplus-6-roth-says-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Smith Micro closes +6% as Roth says Buy</a></h4><ul><li>        Roth Capital starts Smith Micro (NASDAQ:<a href='https://seekingalpha.com/symbol/SMSI' title='Smith Micro Software, Inc.'>SMSI</a>) at Buy with a $4 price target, according to StreetAccount.</li><li>               In early September, Smith Micro <a href=\"https://seekingalpha.com/pr/17260762-smith-micro-explore-strategic-options-quicklink-iot-product-line\" target=\"_blank\">announced plans</a> to explore strategic options for its QuickLink IoT product line, which was soon expanded <a href=\"https://seekingalpha.com/pr/17267082-smith-micro-announces-safepath-connected-life-platform\" target=\"_blank\">with the launch</a> of the SafePath Connected Life Platform. &nbsp;&nbsp;</li><li>               SMSI shares closed today&nbsp;<font color='green'>up 6.4%</font>&nbsp;to $2.68. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3394274\" data-linked=\"Smith Micro closes +6% as Roth says Buy\" data-tweet=\"$SMSI - Smith Micro closes +6% as Roth says Buy https://seekingalpha.com/news/3394274-smith-micro-closesplus-6-roth-says-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3394274-smith-micro-closesplus-6-roth-says-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394272\" data-ts=\"1538429063\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEN\" target=\"_blank\">TEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394272-tenneco-closes-federal-mogul-deal-icahn-confirms-9_9-active-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tenneco closes Federal-Mogul deal; Icahn confirms 9.9% active stake</a></h4><ul>     <li>Tenneco (NYSE:<a href='https://seekingalpha.com/symbol/TEN' title='Tenneco Inc.'>TEN</a>)&nbsp;<font color='green'>+2.4%</font> after-hours after saying it <a href=\"https://seekingalpha.com/pr/17286878-tenneco-announces-close-federal-mogul-acquisition\" target=\"_blank\">completed its acquisition</a> of Federal-Mogul from Icahn Enterprises (NYSE:<a href='https://seekingalpha.com/symbol/IEP' title='Icahn Enterprises L.P.'>IEP</a>) and Icahn <a href=\"https://www.sec.gov/Archives/edgar/data/921669/000092846418000144/tensch13d100118.htm\" target=\"_blank\">confirms a 9.9% active stake</a> in TEN.</li>     <li>TEN says $800M was financed through a new senior       credit facility that will replace its existing senior credit facilities and senior facilities of Federal-Mogul ; the new senior credit facility consists of a $1.7B term loan A, a $1.7B term loan B and a $1.5B revolving credit facility.</li>     <li>The closing precedes the planned separation of the combined businesses into an Aftermarket and Ride Performance company and a Powertrain Technology company, which is expected to be complete in late 2019.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3394272\" data-linked=\"Tenneco closes Federal-Mogul deal; Icahn confirms 9.9% active stake\" data-tweet=\"$TEN $TEN $IEP - Tenneco closes Federal-Mogul deal; Icahn confirms 9.9% active stake https://seekingalpha.com/news/3394272-tenneco-closes-federal-mogul-deal-icahn-confirms-9_9-active-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3394272-tenneco-closes-federal-mogul-deal-icahn-confirms-9_9-active-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394248\" data-ts=\"1538426126\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394248-legion-to-pressure-papa-johns-after-taking-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Legion to pressure Papa John&#39;s after taking stake</a></h4><ul><li>Papa John's International &lt;PZZA&gt; swings higher after stakeholder Legion Partners says it may engage in talks with the company, including potential discussion on the ownership structure and paths to increase value.</li><li>Legion holds an active stake of 5.5% in Papa John's.</li><li><a href=\"https://seekingalpha.com/filing/4186375\" target=\"_blank\">SEC Form 13D</a></li><li>PZZA&nbsp;<font color='green'>+1.0%</font>&nbsp;AH to $49.74.</li></ul><div class=\"tiny-share-widget\" data-id=\"3394248\" data-linked=\"Legion to pressure Papa John&#39;s after taking stake\" data-tweet=\"Legion to pressure Papa John&#39;s after taking stake https://seekingalpha.com/news/3394248-legion-to-pressure-papa-johns-after-taking-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3394248-legion-to-pressure-papa-johns-after-taking-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394240\" data-ts=\"1538425668\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SFIX\" target=\"_blank\">SFIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394240-post-earnings-decline-for-stitch-fix\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Post-earnings decline for Stitch Fix</a></h4><ul><li>Stitch Fix (NASDAQ:<a href='https://seekingalpha.com/symbol/SFIX' title='Stitch Fix, Inc.'>SFIX</a>) slides despite topping FQ4 estimates.</li><li>The online retailer reports its active client count increased 25% during the quarter to 2.7M.</li><li>Revenue was up 23% to $318M, while adjusted EBITDA came in at $11.1M.</li><li>Shares of Stitch Fix are&nbsp;<font color='red'>down 16.8%</font>&nbsp;AH to $37.15.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3394231-stitch-fix-beats-0_13-revenue-line\" target=\"_blank\">Stitch Fix beats by $0.13,  revenue in-line</a> (Oct. 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3394240\" data-linked=\"Post-earnings decline for Stitch Fix\" data-tweet=\"$SFIX - Post-earnings decline for Stitch Fix https://seekingalpha.com/news/3394240-post-earnings-decline-for-stitch-fix?source=tweet\" data-url=\"https://seekingalpha.com/news/3394240-post-earnings-decline-for-stitch-fix\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394237\" data-ts=\"1538425429\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADRO\" target=\"_blank\">ADRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394237-janssen-bails-on-developing-aduros-listeria-strains\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Janssen bails on developing Aduro&#39;s Listeria strains</a></h4><ul><li>Aduro Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/ADRO' title='Aduro Biotech'>ADRO</a>) <a href=\"https://www.sec.gov/Archives/edgar/data/1435049/000119312518289503/d619516d8k.htm\" target=\"_blank\">reports </a>that licensee Janssen Biotech (NYSE:<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a>) has notified it that it will terminate its exclusive global license agreement to develop treatments containing attenuated <em>Listeria </em>strains ADU-214, ADU-741 and GVAX Prostate for all indications.</li><li>All rights and related IP will be returned to Aduro.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3069986-aduro-bags-22_4m-ladd-related-milestones-janssen-biotech\" target=\"_blank\">Aduro bags $22.4M in LADD-related milestones from Janssen Biotech</a> (Feb. 1, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3394237\" data-linked=\"Janssen bails on developing Aduro&#39;s Listeria strains\" data-tweet=\"$ADRO $ADRO $JNJ - Janssen bails on developing Aduro&#39;s Listeria strains https://seekingalpha.com/news/3394237-janssen-bails-on-developing-aduros-listeria-strains?source=tweet\" data-url=\"https://seekingalpha.com/news/3394237-janssen-bails-on-developing-aduros-listeria-strains\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394217\" data-ts=\"1538424441\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GWPH\" target=\"_blank\">GWPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394217-gw-pharma-readies-300m-ads-offering-shares-slip-2-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GW Pharma readies $300M ADS offering; shares slip 2% after hours</a></h4><ul><li>GW Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/GWPH' title='GW Pharmaceuticals plc'>GWPH</a>) eases<font color='red'> 2%</font>&nbsp;after hours on the heels of its planned <a href=\"https://seekingalpha.com/pr/17286800-gw-pharmaceuticals-announces-proposed-public-offering-adss\" target=\"_blank\">$300M offering</a> of American Depositary Shares (ADSs). Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3394217\" data-linked=\"GW Pharma readies $300M ADS offering; shares slip 2% after hours\" data-tweet=\"$GWPH - GW Pharma readies $300M ADS offering; shares slip 2% after hours https://seekingalpha.com/news/3394217-gw-pharma-readies-300m-ads-offering-shares-slip-2-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3394217-gw-pharma-readies-300m-ads-offering-shares-slip-2-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394211\" data-ts=\"1538423838\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENTG\" target=\"_blank\">ENTG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394211-deutsche-bank-upgrades-entegris-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deutsche Bank upgrades Entegris to Buy</a></h4><ul><li>        Deutsche Bank upgrades Entegris (NASDAQ:<a href='https://seekingalpha.com/symbol/ENTG' title='Entegris, Inc.'>ENTG</a>) from Hold to Buy but drops the price target by $2 to $38, according to StreetAccount.</li><li>               Entegris is expected to report earnings premarket on October 25. <a href=\"https://seekingalpha.com/symbol/ENTG/earnings/estimates\" target=\"_blank\">Consensus estimates</a> for the quarter put revenue at $404.63M and EPS at $0.51.&nbsp;</li><li>               Entegris shares are heading towards today&rsquo;s close&nbsp;<font color='green'>up 1.1%</font>&nbsp;to $29.26.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3394211\" data-linked=\"Deutsche Bank upgrades Entegris to Buy\" data-tweet=\"$ENTG - Deutsche Bank upgrades Entegris to Buy https://seekingalpha.com/news/3394211-deutsche-bank-upgrades-entegris-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3394211-deutsche-bank-upgrades-entegris-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394206\" data-ts=\"1538423238\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KEYW\" target=\"_blank\">KEYW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394206-keywplus-1_6-on-initiation-outperform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KeyW +1.6% on initiation at Outperform</a></h4><ul><li>        William Blair starts KeyW (NASDAQ:<a href='https://seekingalpha.com/symbol/KEYW' title='KEYW Holding'>KEYW</a>) at Outperform, according to StreetAccount.</li><li>               In the past two months, KeyW won a $500M Defense Intelligence Agency contract, a $100M contract with a classified customer, and a $135M GSA purchase agreement.&nbsp;</li><li>               KeyW shares are&nbsp;<font color='green'>up 1.6%</font>&nbsp;to $8.80. Shares are&nbsp;<font color='green'>up 3.6%</font>&nbsp;this month,&nbsp;<font color='red'>down 1%</font>&nbsp;in the quarter, and&nbsp;<font color='green'>up 47.5%&nbsp;</font>YTD. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3384525-keyw-plus-3_5-percent-100m-contract-classified-customer\" target=\"_blank\">KeyW +3.5% on over $100M contract with classified customer</a> (Aug. 21)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3385910-keyw-gets-gsa-purchase-agreement-valued-135m\" target=\"_blank\">KeyW gets GSA purchase agreement valued at $135M</a> (Aug. 27)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392836-keyw-secures-defense-intelligence-agency-500m-helios-idiq-contract\" target=\"_blank\">KeyW secures Defense Intelligence Agency $500M HELIOS IDIQ contract</a> (Sept. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3394206\" data-linked=\"KeyW +1.6% on initiation at Outperform\" data-tweet=\"$KEYW - KeyW +1.6% on initiation at Outperform https://seekingalpha.com/news/3394206-keywplus-1_6-on-initiation-outperform?source=tweet\" data-url=\"https://seekingalpha.com/news/3394206-keywplus-1_6-on-initiation-outperform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394204\" data-ts=\"1538422781\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTGN\" target=\"_blank\">NTGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394204-neon-therapeutics-up-32-on-nobel-prize-for-founder-allison\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neon Therapeutics up 32% on Nobel Prize for founder Allison</a></h4><ul><li>Thinly traded micro cap Neon Therapeutics (<a href='https://seekingalpha.com/symbol/NTGN' title='Neon Therapeutics'>NTGN</a> <font color='green'>+32.1%</font>) jumps on a 5x surge in volume following the <a href=\"https://seekingalpha.com/pr/17286235-neon-therapeutics-congratulates-founder-james-p-allison-ph-d-2018-nobel-prize-physiology\" target=\"_blank\">news </a>that scientific founder James Allison, Ph.D. won the Nobel Prize in Physiology or Medicine for his work in the discovery of cancer therapy based on inhibiting negative immune system regulation (i.e., an immune checkpoint inhibitor).</li></ul><div class=\"tiny-share-widget\" data-id=\"3394204\" data-linked=\"Neon Therapeutics up 32% on Nobel Prize for founder Allison\" data-tweet=\"$NTGN - Neon Therapeutics up 32% on Nobel Prize for founder Allison https://seekingalpha.com/news/3394204-neon-therapeutics-up-32-on-nobel-prize-for-founder-allison?source=tweet\" data-url=\"https://seekingalpha.com/news/3394204-neon-therapeutics-up-32-on-nobel-prize-for-founder-allison\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394195\" data-ts=\"1538421102\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LOGM\" target=\"_blank\">LOGM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394195-oppenheimer-ups-logmein-to-outperform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oppenheimer ups LogMeIn to Outperform</a></h4><ul><li>        Oppenheimer upgrades LogMeIn (NASDAQ:<a href='https://seekingalpha.com/symbol/LOGM' title='LogMeIn, Inc.'>LOGM</a>) from Perform to Outperform with a $105 price target, an 18% upside to Friday&rsquo;s close.&nbsp;</li><li>               Analyst Shaul Eyal cites stabilizing customer retention trends and the attractive valuation.&nbsp;</li><li>               Source: StreetAccount.&nbsp;</li><li>               LogMeIn shares are&nbsp;<font color='red'>down 1%</font>&nbsp;to $88.20.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3394195\" data-linked=\"Oppenheimer ups LogMeIn to Outperform\" data-tweet=\"$LOGM - Oppenheimer ups LogMeIn to Outperform https://seekingalpha.com/news/3394195-oppenheimer-ups-logmein-to-outperform?source=tweet\" data-url=\"https://seekingalpha.com/news/3394195-oppenheimer-ups-logmein-to-outperform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394193\" data-ts=\"1538420132\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTSL\" target=\"_blank\">MTSL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394193-technology-top-5-gainers-losers-of-2_55-pm-10-01-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 2.55 PM (10/01/2018)</a></h4><ul>     <li><strong>Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/MTSL' title='MER Telemanagement Solutions Ltd.'>MTSL</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/SYNC' title='Synacor'>SYNC</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/POLA' title='Polar Power Inc'>POLA</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/AVLR' title='Avalara'>AVLR</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/CTG' title='Computer Task Group Inc.'>CTG</a> <font color='green'>+6%</font>.</li>     <li><strong>Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/INFN' title='Infinera Corporation'>INFN</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/LFIN' title='LongFin Corp.A'>OTCPK:LFIN</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/NCTY' title='The9 Limited'>NCTY</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/VICR' title='Vicor Corporation'>VICR</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/CDLX' title='Cardlytics, Inc.'>CDLX</a> <font color='red'>-9%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3394193\" data-linked=\"Technology - Top 5 Gainers / Losers as of 2.55 PM (10/01/2018)\" data-tweet=\"$MTSL $MTSL $SYNC - Technology - Top 5 Gainers / Losers as of 2.55 PM (10/01/2018) https://seekingalpha.com/news/3394193-technology-top-5-gainers-losers-of-2_55-pm-10-01-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3394193-technology-top-5-gainers-losers-of-2_55-pm-10-01-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394191\" data-ts=\"1538420102\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394191-energy-names-lead-gains-oil-surges-to-four-year-high\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy names lead gains as oil surges to four-year high</a></h4><ul><li>WTI crude oil has added&nbsp;<font color='green'>nearly another 3%</font>, now at $75.37 per barrel, its highest intraday level since 2014. <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>&nbsp;<font color='green'>+2.9%</font></li><li>That's helping the Energy Select SPDR (<a href='https://seekingalpha.com/symbol/XLE' title='Energy Select Sector SPDR ETF'>XLE</a> <font color='green'>+1.7%</font>) far outperform the S&amp;P 500's&nbsp;<font color='green'>0.4% advance</font>.</li><li>What's moving oil? Take your pick, but the team at Commerzbank sees Iranian oil exports tumbling by about 2M barrels per day, with not a lot of spare OPEC capacity to make for that.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/XLE' title='Energy Select Sector SPDR ETF'>XLE</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UWT' title='VelocityShares 3X Long Crude ETN'>UWT</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/VDE' title='Vanguard Energy ETF'>VDE</a>, <a href='https://seekingalpha.com/symbol/DWT' title='VelocityShares 3x Inverse Crude Oil ETN'>DWT</a>, <a href='https://seekingalpha.com/symbol/ERX' title='Direxion Daily Energy Bull 3x Shares ETF'>ERX</a>, <a href='https://seekingalpha.com/symbol/OIH' title='VanEck Vectors Oil Services ETF'>OIH</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='Invesco DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/ERY' title='Direxion Daily Energy Bear 3x Shares ETF'>ERY</a>, <a href='https://seekingalpha.com/symbol/DIG' title='ProShares Ultra Oil & Gas ETF'>DIG</a>, <a href='https://seekingalpha.com/symbol/UGA' title='The United States Gasoline ETF, LP'>UGA</a>, <a href='https://seekingalpha.com/symbol/BGR' title='BlackRock Energy&Resources Trust'>BGR</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/FENY' title='Fidelity MSCI Energy Index ETF'>FENY</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/IYE' title='iShares U.S. Energy ETF'>IYE</a>, <a href='https://seekingalpha.com/symbol/DUG' title='ProShares UltraShort Oil & Gas ETF'>DUG</a>, <a href='https://seekingalpha.com/symbol/FIF' title='First Trust Energy Infrastructure Fund'>FIF</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/RYE' title='Invesco S&P Equal Weight Energy ETF'>RYE</a>, <a href='https://seekingalpha.com/symbol/PXJ' title='Invesco Dynamic Oil & Gas Services Portfolio ETF'>PXJ</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3394191\" data-linked=\"Energy names lead gains as oil surges to four-year high\" data-tweet=\"$USO $XLE $OIL - Energy names lead gains as oil surges to four-year high https://seekingalpha.com/news/3394191-energy-names-lead-gains-oil-surges-to-four-year-high?source=tweet\" data-url=\"https://seekingalpha.com/news/3394191-energy-names-lead-gains-oil-surges-to-four-year-high\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394190\" data-ts=\"1538420069\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RYAAY\" target=\"_blank\">RYAAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394190-down-day-for-global-airline-sector\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Down day for global airline sector</a></h4><ul> <li>Airline stocks are reacting to the push higher in crude oil prices. The sector was also roughed up earlier in Europe after budget carrier Ryanair lowered its profit guidance for the year and is seeing Latin America carriers trade down on regulatory and FX concerns.</li> <li>Notable decliners include Ryanair (<a href='https://seekingalpha.com/symbol/RYAAY' title='Ryanair Holdings PLC'>RYAAY</a> <font color='red'>-16.6%</font>), Lufthansa (<a href='https://seekingalpha.com/symbol/DLAKF' title='Deutsche Lufthansa AG'>OTCQX:DLAKF</a>) <font color='red'>-2.1%</font>, International Consolidated Airlines (<a href='https://seekingalpha.com/symbol/ICAGY' title='International Consolidated Airlines Group SA ADR'>OTCPK:ICAGY</a>) <font color='red'>-2.6%</font>, LATAM Airlines (<a href='https://seekingalpha.com/symbol/LTM' title='LATAM Airlines Group S.A.'>LTM</a> <font color='red'>-2.3%</font>), Hawaiian Holdings (<a href='https://seekingalpha.com/symbol/HA' title='Hawaiian Holdings, Inc.'>HA</a> <font color='red'>-4.9%</font>), SkyWest (<a href='https://seekingalpha.com/symbol/SKYW' title='SkyWest, Inc.'>SKYW</a> <font color='red'>-4.5%</font>), Copa Holdings (<a href='https://seekingalpha.com/symbol/CPA' title='Copa Holdings, S.A.'>CPA</a> <font color='red'>-3%</font>), Gol Linhas (<a href='https://seekingalpha.com/symbol/GOL' title='GOL Linhas Aéreas Inteligentes S.A.'>GOL</a> <font color='red'>-1.6%</font>), Azul (<a href='https://seekingalpha.com/symbol/AZUL' title='Azul'>AZUL</a> <font color='red'>-4.4%</font>), Mesa Air (<a href='https://seekingalpha.com/symbol/MESA' title='Mesa Air Group'>MESA</a> <font color='red'>-4.4%</font>), American Airlines Group (<a href='https://seekingalpha.com/symbol/AAL' title='American Airlines Group'>AAL</a> <font color='red'>-3%</font>), Spirit Airlines (<a href='https://seekingalpha.com/symbol/SAVE' title='Spirit Airlines'>SAVE</a> <font color='red'>-2.6%</font>) and Delta Air Lines (<a href='https://seekingalpha.com/symbol/DAL' title='Delta Air Lines, Inc.'>DAL</a> <font color='red'>-1.6%</font>).</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3394190\" data-linked=\"Down day for global airline sector\" data-tweet=\"$RYAAY $RYAAY $DLAKF - Down day for global airline sector https://seekingalpha.com/news/3394190-down-day-for-global-airline-sector?source=tweet\" data-url=\"https://seekingalpha.com/news/3394190-down-day-for-global-airline-sector\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394188\" data-ts=\"1538419921\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HEAR\" target=\"_blank\">HEAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394188-turtle-beach-dips-new-pc-headsets-hit-stores\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Turtle Beach dips as new PC headsets hit stores</a></h4><ul><li>           Turtle Beach (<a href='https://seekingalpha.com/symbol/HEAR' title='Turtle Beach Corporation'>HEAR</a> <font color='red'>-1.8%</font>) shares dip as its new line of Atlas PC gaming headsets <a href=\"https://seekingalpha.com/pr/17285888-global-gaming-audio-leader-turtle-beach-launches-pc-gaming-three-new-atlas-gaming-headsets\" target=\"_blank\">hits stores</a> worldwide. </li><li> The line includes the Atlas One ($49.95), Atlas Three ($79.95), and the Atlas Elite ($99.95). </li><li> The Atlas line was first announced in August and HEAR had gained immediately after the news broke.&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3383497-turtle-beach-plus-2_3-percent-new-gaming-headset-line\" target=\"_blank\">Turtle Beach +2.3% on new gaming headset line</a> (Aug. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3394188\" data-linked=\"Turtle Beach dips as new PC headsets hit stores\" data-tweet=\"$HEAR - Turtle Beach dips as new PC headsets hit stores https://seekingalpha.com/news/3394188-turtle-beach-dips-new-pc-headsets-hit-stores?source=tweet\" data-url=\"https://seekingalpha.com/news/3394188-turtle-beach-dips-new-pc-headsets-hit-stores\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394187\" data-ts=\"1538419865\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INFN\" target=\"_blank\">INFN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394187-infinera-takes-issue-mkm-report-on-dilution-customer-loss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Infinera takes issue with MKM report on dilution, customer loss</a></h4><ul>   <li>Infinera (NASDAQ:<a href='https://seekingalpha.com/symbol/INFN' title='Infinera Corporation'>INFN</a>) is <a href=\"https://seekingalpha.com/pr/17286669-infinera-comments-recent-market-report\" target=\"_blank\">pushing back</a> on an analyst's downgrade, taking issue with two parts of the note.</li>    <li>Shares pared losses slightly but are still <font color='red'>down 16.6%</font> on the day.</li>    <li>MKM Partners this morning <a href=\"https://seekingalpha.com/news/3393966-infinera-minus-13_7-percent-analyst-predicts-major-customer-loss\" target=\"_blank\">cut the stock to Sell</a>, from Neutral, and slashed its price target to $5.50 from $10.</li>    <li>Infinera says an analyst's report \"erroneously suggested that Infinera would need to issue additional shares to close the Coriant transaction.\" The shares issued on close of the deal is fixed at 20,974,384, Infinera notes.</li>    <li>It also objected to MKM's conclusion that Infinera was likely to lose a major customer, CenturyLink, to rival Ciena (<a href=\"http://seekingalpha.com/symbol/CIEN\" target=\"_blank\">CIEN</a> <font color='red'>-5.1%</font>).</li>    <li>\"Subsequent to the publication of this analyst report, Infinera confirmed with CenturyLink executive management that a final decision has not been made,\" Infinera says in its statement.</li>    <li>Infinera notes it's in its investor quiet period with the quarter having wrapped on Saturday; it expects to add additional details around expectations for the Coriant deal with its Q3 earnings call.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3394187\" data-linked=\"Infinera takes issue with MKM report on dilution, customer loss\" data-tweet=\"$INFN $INFN $CIEN - Infinera takes issue with MKM report on dilution, customer loss https://seekingalpha.com/news/3394187-infinera-takes-issue-mkm-report-on-dilution-customer-loss?source=tweet\" data-url=\"https://seekingalpha.com/news/3394187-infinera-takes-issue-mkm-report-on-dilution-customer-loss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394186\" data-ts=\"1538419817\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IVPAF\" target=\"_blank\">IVPAF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394186-ivanhoe-minesplus-9-after-third-major-congo-copper-discovery\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ivanhoe Mines +9% after third major Congo copper discovery</a></h4><ul>     <li>Ivanhoe Mines (<a href='https://seekingalpha.com/symbol/IVPAF' title='Ivanhoe Mines Ltd.'>OTCQX:IVPAF</a> <font color='green'>+9.3%</font>) surges after announcing a <a href=\"https://www.ivanhoemines.com/news/2018/ivanhoe-mines-announces-the-makoko-copper-discovery-on-its-100-owned-western-foreland-exploration-licences-near-kamoa-kakula-in/\" target=\"_blank\">significant new discovery</a> of high-grade copper on its 100%-owned Western Foreland asset in the Democratic Republic of Congo.</li>     <li>The Makoko discovery is Ivanhoe&rsquo;s third major copper find in the  DRC and the first of multiple high-potential target areas  identified by the company&rsquo;s exploration team to be tested by drilling.</li>     <li>Ivanhoe says the discovery remains open in all directions while it continues drilling other targets on Western Foreland for high -grade copper.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3394186\" data-linked=\"Ivanhoe Mines +9% after third major Congo copper discovery\" data-tweet=\"$IVPAF - Ivanhoe Mines +9% after third major Congo copper discovery https://seekingalpha.com/news/3394186-ivanhoe-minesplus-9-after-third-major-congo-copper-discovery?source=tweet\" data-url=\"https://seekingalpha.com/news/3394186-ivanhoe-minesplus-9-after-third-major-congo-copper-discovery\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394184\" data-ts=\"1538419038\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RAMP\" target=\"_blank\">RAMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394184-acxiom-holdingsminus-2-ahead-of-tomorrows-move-to-nyse\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acxiom Holdings -2% ahead of tomorrow&#39;s move to the NYSE</a></h4><ul><li>        Acxiom Holdings (NYSE:<a href='https://seekingalpha.com/symbol/ACXM' title='LiveRamp Holdings, Inc.'>ACXM</a>) drops ahead of tomorrow&rsquo;s planned move to the NYSE with a name change to LiveRamp and the new ticker &ldquo;RAMP&rdquo;.</li><li>               The change follows the <a href=\"https://seekingalpha.com/pr/17276840-acxiom-shareholders-approve-ams-sale\" target=\"_blank\">recent sale</a> of the company&rsquo;s Acxiom Marketing Solutions business to Interpublic Group with the transaction closing today. &nbsp;&nbsp;</li><li>                  Acxiom filed its <a href=\"https://www.sec.gov/Archives/edgar/data/733269/000087666118001045/0000876661-18-001045-index.htm\" target=\"_blank\">CERT form</a> today showing that the NYSE listing was approved.    </li><li>               Acxiom shares are&nbsp;<font color='red'>down 2%</font>&nbsp;to $48.44.&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3394184\" data-linked=\"Acxiom Holdings -2% ahead of tomorrow&#39;s move to the NYSE\" data-tweet=\"$RAMP - Acxiom Holdings -2% ahead of tomorrow&#39;s move to the NYSE https://seekingalpha.com/news/3394184-acxiom-holdingsminus-2-ahead-of-tomorrows-move-to-nyse?source=tweet\" data-url=\"https://seekingalpha.com/news/3394184-acxiom-holdingsminus-2-ahead-of-tomorrows-move-to-nyse\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394182\" data-ts=\"1538418465\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OMER\" target=\"_blank\">OMER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394182-omeros-oms721-shows-positive-effect-in-mid-stage-iga-nephropathy-study-in-steroid-free\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Omeros&#39; OMS721 shows positive effect in mid-stage IgA nephropathy study in steroid -free patients</a></h4><ul><li>Omeros (<a href='https://seekingalpha.com/symbol/OMER' title='Omeros Corporation'>OMER</a> <font color='red'>-5.3%</font>) <a href=\"https://seekingalpha.com/pr/17286670-omeros-corporation-announces-additional-positive-data-oms721-iga-nephropathy\" target=\"_blank\">announces </a>positive results from a Phase 2 clinical trial evaluating OMS721 in corticosteroid therapy-naive patients with immunoglobulin A (IgA) nephropathy.</li><li>The treatment effect, reductions in urine protein levels, was on par with that observed in IgA nephropathy patients on steroid therapy.</li><li>Additional data will be submitted for presentation at a future medical conference.</li><li>A Phase 3 study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03608033?lead=omeros&amp;phase=2&amp;rank=1\" target=\"_blank\">ARTEMIS-IGAN</a>, is ongoing with an estimated primary completion date of May 2020.</li><li>Shares will resume trading at 2:45 pm ET.</li></ul><div class=\"tiny-share-widget\" data-id=\"3394182\" data-linked=\"Omeros&#39; OMS721 shows positive effect in mid-stage IgA nephropathy study in steroid -free patients\" data-tweet=\"$OMER - Omeros&#39; OMS721 shows positive effect in mid-stage IgA nephropathy study in steroid -free patients https://seekingalpha.com/news/3394182-omeros-oms721-shows-positive-effect-in-mid-stage-iga-nephropathy-study-in-steroid-free?source=tweet\" data-url=\"https://seekingalpha.com/news/3394182-omeros-oms721-shows-positive-effect-in-mid-stage-iga-nephropathy-study-in-steroid-free\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>258&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394181\" data-ts=\"1538417963\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HUSKF\" target=\"_blank\">HUSKF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394181-husky-sees-meg-bet-on-price-differentials-returning-to-normal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Husky sees MEG as bet on price differentials returning to normal</a></h4><ul>     <li>Husky Energy (<a href='https://seekingalpha.com/symbol/HUSKF' title='Husky Energy Inc.'>OTCPK:HUSKF</a> <font color='red'>-5.6%</font>) CEO Rob Peabody says his company&rsquo;s <a href=\"http://www.huskyenergy.ca/news/release.asp?release_id=2206357\" target=\"_blank\">hostile C$6.4B bid</a> for MEG Energy (<a href='https://seekingalpha.com/symbol/MEGEF' title='Meg Energy Corp.'>OTCPK:MEGEF</a> <font color='green'>+38%</font>) reflects the need for Canadian oil companies to own integrated assets from production to refineries in order to <a href=\"https://www.reuters.com/article/us-meg-energy-m-a-husky-energy/husky-sees-meg-as-potential-hand-in-glove-canada-oil-sands-merger-idUSKCN1MB2SW\" target=\"_blank\">manage the deep price discounts on Canadian crude</a>.</li><li>Husky&rsquo;s bid for highly indebted MEG is a bet that MEG&rsquo;s production assets will be lucrative once price differentials return to normal, but analysts say some investors own Husky shares for its low exposure to heavy oil differentials and may be disappointed by a bid that increases such risks.</li><li>MEG potentially could find another suitor with a more attractive offer, says Eight Capital analyst Phil Skolnick, adding that Imperial Oil (<a href='https://seekingalpha.com/symbol/IMO' title='Imperial Oil Ltd'>IMO</a> <font color='green'>+3.1%</font>) and Suncor Energy (<a href='https://seekingalpha.com/symbol/SU' title='Suncor Energy Inc.'>SU</a> <font color='green'>+1.9%</font>) are potential bidders.</li><li>Peabody says Husky will begin to meet soon with MEG shareholders about the deal but would welcome talks with MEG&rsquo;s board.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3394181\" data-linked=\"Husky sees MEG as bet on price differentials returning to normal\" data-tweet=\"$HUSKF $HUSKF $MEGEF - Husky sees MEG as bet on price differentials returning to normal https://seekingalpha.com/news/3394181-husky-sees-meg-bet-on-price-differentials-returning-to-normal?source=tweet\" data-url=\"https://seekingalpha.com/news/3394181-husky-sees-meg-bet-on-price-differentials-returning-to-normal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394180\" data-ts=\"1538417722\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OMER\" target=\"_blank\">OMER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394180-omeros-shares-halted-pending-news-shares-down-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Omeros shares halted pending news; shares down 5%</a></h4><ul><li>Nasdaq has suspended trading in Omeros (<a href='https://seekingalpha.com/symbol/OMER' title='Omeros Corporation'>OMER</a> <font color='red'>-5.2%</font>) pending the release of news.</li></ul><div class=\"tiny-share-widget\" data-id=\"3394180\" data-linked=\"Omeros shares halted pending news; shares down 5%\" data-tweet=\"$OMER - Omeros shares halted pending news; shares down 5% https://seekingalpha.com/news/3394180-omeros-shares-halted-pending-news-shares-down-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3394180-omeros-shares-halted-pending-news-shares-down-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>62&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394179\" data-ts=\"1538417653\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DVA\" target=\"_blank\">DVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394179-davita-to-pay-270m-to-settle-charges-of-inflated-of-medicare-payments\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DaVita to pay $270M to settle charges of inflated of Medicare payments</a></h4><ul><li>DaVita (<a href='https://seekingalpha.com/symbol/DVA' title='DaVita HealthCare Partners Inc.'>DVA</a> <font color='green'>+3.6%</font>) subsidiary DaVita Medical Holdings LLC has agreed to pay $270M to <a href=\"https://www.justice.gov/opa/pr/medicare-advantage-provider-pay-270-million-settle-false-claims-act-liabilities\" target=\"_blank\">settle charges </a>that it provided inaccurate information that caused Medicare Advantage &#40;MA&#41; Plans to receive inflated payments from Medicare.</li><li>MA plans pay a fixed risk-adjusted monthly amount for beneficiaries to account fo the higher costs of caring for people requiring greater care. DaVita operated a medical services organization &#40;MSO&#41; that contracted with MA organizations and received a share of Medicare payments.</li><li>DaVita voluntarily reported to the government certain practices by a California-based independent physician association that it acquired in 2012 that caused the group to submit incorrect diagnostic codes to CMS which inflated reimbursement payments. The DOJ says it agreed to a favorable settlement in light of DaVita's cooperation in the matter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3394179\" data-linked=\"DaVita to pay $270M to settle charges of inflated of Medicare payments\" data-tweet=\"$DVA - DaVita to pay $270M to settle charges of inflated of Medicare payments https://seekingalpha.com/news/3394179-davita-to-pay-270m-to-settle-charges-of-inflated-of-medicare-payments?source=tweet\" data-url=\"https://seekingalpha.com/news/3394179-davita-to-pay-270m-to-settle-charges-of-inflated-of-medicare-payments\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394177\" data-ts=\"1538417140\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LVS\" target=\"_blank\">LVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394177-macau-stocks-hang-tough-following-weak-september\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Macau stocks hang tough following weak September</a></h4><ul> <li>Nomura Instinet expects Macau gross gaming revenue growth of 5% to 10% in October as Golden Week holiday demand and a bounce back in traffic following the typhoon last month factors in.</li> <li>The forecast for Macau looks a bit more impressive considering that it runs up against a strong +22% October GGR comparison from a year ago.</li> <li>Price check: Las Vegas Sands (<a href='https://seekingalpha.com/symbol/LVS' title='Las Vegas Sands Corp.'>LVS</a> <font color='green'>+0.5%</font>) is bouncing slightly off the 52-week low etched out earlier and Melco Resorts &amp; Entertainment (<a href='https://seekingalpha.com/symbol/MLCO' title='Melco Resorts & Entertainment Limited ADR'>MLCO</a> <font color='green'>+0.7%</font>) is also in positive territory. Wynn Resorts (<a href='https://seekingalpha.com/symbol/WYNN' title='Wynn Resorts, Limited'>WYNN</a> <font color='red'>-0.9%</font>) and MGM Resorts (<a href='https://seekingalpha.com/symbol/MGM' title='MGM Resorts International'>MGM</a> <font color='red'>-2.9%</font>)&nbsp;are lower following the soft report on September Macau GGR. MGM is also lapping the one-year anniversary of the mass shooting at the Mandalay Bay.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3393941-macau-gaming-revenue-plus-3-percent-september\" target=\"_blank\">Macau gaming revenue +3% during September</a> (Oct. 1)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3394177\" data-linked=\"Macau stocks hang tough following weak September\" data-tweet=\"$LVS $LVS $MLCO - Macau stocks hang tough following weak September https://seekingalpha.com/news/3394177-macau-stocks-hang-tough-following-weak-september?source=tweet\" data-url=\"https://seekingalpha.com/news/3394177-macau-stocks-hang-tough-following-weak-september\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394176\" data-ts=\"1538416877\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IGC\" target=\"_blank\">IGC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394176-energy-materials-top-gainers-losers-of-2-00-pm-10-01-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials  - Top Gainers / Losers as of 2:00 PM (10/01/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/UPL' title='Ultra Petroleum Corp.'>UPL</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/PGLC' title='Pershing Gold Corporation'>PGLC</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/JONE' title='Jones Energy, Inc.'>OTC:JONE</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/UEC' title='Uranium Energy Corp'>UEC</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/FGP' title='Ferrellgas Partners L.P'>FGP</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/LPI' title='Laredo Petroleum Holdings, Inc.'>LPI</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3394176\" data-linked=\"Energy/Materials  - Top Gainers / Losers as of 2:00 PM (10/01/2018)\" data-tweet=\"$IGC $IGC $UPLC - Energy/Materials - Top Gainers / Losers as of 2:00 PM (10/01/2018) https://seekingalpha.com/news/3394176-energy-materials-top-gainers-losers-of-2-00-pm-10-01-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3394176-energy-materials-top-gainers-losers-of-2-00-pm-10-01-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394175\" data-ts=\"1538416615\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOOG\" target=\"_blank\">GOOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394175-now-testing-play-assassins-creed-in-google-chrome\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Now testing: Play Assassin&#39;s Creed in Google Chrome</a></h4><ul><li>                   Google (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a> <font color='green'>+0.4%</font>)(<a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a> <font color='green'>+0.3%</font>) <a href=\"https://techcrunch.com/2018/10/01/google-gets-into-game-streaming-with-project-stream-and-assassins-creed-odyssey-in-chrome/?utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+Techcrunch+%28TechCrunch%29\" target=\"_blank\">unveils</a> Project Stream, a &ldquo;technical test&rdquo; for game streaming through the Chrome browser. The launch includes a partnership with Ubisoft (<a href='https://seekingalpha.com/symbol/UBSFY' title='UbiSoft Entertainment Inc. ADR'>OTCPK:UBSFY</a> <font color='green'>+7.5%</font>). Select players will get free access to Assassin&rsquo;s Creed Odyssey for the test period, which opens on October 5.&nbsp; </li><li> Key quote from Google&rsquo;s announcement: &ldquo;When streaming TV or movies, consumers are comfortable with a few seconds of buffering at the start, but streaming high-quality games requires latency measured in milliseconds, with no graphics degradation.&rdquo; </li><li> You can sign up to be a Project Stream tester <a href=\"https://projectstream.google.com/aco/signup\" target=\"_blank\">here</a>.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3394175\" data-linked=\"Now testing: Play Assassin&#39;s Creed in Google Chrome\" data-tweet=\"$GOOG $GOOG $GOOGL - Now testing: Play Assassin&#39;s Creed in Google Chrome https://seekingalpha.com/news/3394175-now-testing-play-assassins-creed-in-google-chrome?source=tweet\" data-url=\"https://seekingalpha.com/news/3394175-now-testing-play-assassins-creed-in-google-chrome\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394168\" data-ts=\"1538415032\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DPZ\" target=\"_blank\">DPZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394168-down-day-for-pizza-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Down day for pizza stocks</a></h4><ul> <li>Wells Fargo doesn't see a big market share grab by Domino's Pizza (<a href='https://seekingalpha.com/symbol/DPZ' title='Domino&#39;s Pizza, Inc.'>DPZ</a> <font color='red'>-2.4%</font>) this quarter due to the \"struggles\" of a large U.S. competitor. Analyst Jon Tower keeps a Market Perform rating on DPZ and price target of $255.</li> <li>It sure sounds like the firm is talking about Papa John's International (<a href='https://seekingalpha.com/symbol/PZZA' title='Papa John&#39;s International, Inc.'>PZZA</a> <font color='red'>-2.6%</font>), which has seen sales plummet over the last year. Papa John's is also in the news today for a different reason, with founder John Schnatter in <a href=\"https://www.cnbc.com/video/2018/10/01/papa-johns-john-schnatter-i-am-part-of-the-company-but-dont-want-to-be-ceo.html\" target=\"_blank\">court</a>&nbsp;as the lawsuit he filed against the company progresses.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3394168\" data-linked=\"Down day for pizza stocks\" data-tweet=\"$DPZ $DPZ $PZZA - Down day for pizza stocks https://seekingalpha.com/news/3394168-down-day-for-pizza-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3394168-down-day-for-pizza-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394167\" data-ts=\"1538414899\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTGR\" target=\"_blank\">NTGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394167-netgearminus-3_1-cowen-takes-neutral-stance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Netgear -3.1% as Cowen takes Neutral stance</a></h4><ul>   <li>Netgear (NASDAQ:<a href='https://seekingalpha.com/symbol/NTGR' title='NETGEAR, Inc.'>NTGR</a>) is <font color='red'>off 3.1%</font> after an initiation by Cowen at Market Perform.</li>    <li>The firm set a price target of $63, just a hair over Friday's close of $62.85. The price target now implies 3.4% upside with today's decline.</li>    <li>Shares are near flat over the past quarter, but have <font color='green'>risen 33.4%</font> in the past 12 months.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3394167\" data-linked=\"Netgear -3.1% as Cowen takes Neutral stance\" data-tweet=\"$NTGR - Netgear -3.1% as Cowen takes Neutral stance https://seekingalpha.com/news/3394167-netgearminus-3_1-cowen-takes-neutral-stance?source=tweet\" data-url=\"https://seekingalpha.com/news/3394167-netgearminus-3_1-cowen-takes-neutral-stance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:28 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394164\" data-ts=\"1538414099\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRMD\" target=\"_blank\">CRMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394164-cormedix-resumes-neutrolin-stoked-upward-march-shares-ahead-25\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CorMedix resumes Neutrolin-stoked upward march, shares ahead 25%</a></h4><ul><li>Micro cap CorMedix (<a href='https://seekingalpha.com/symbol/CRMD' title='CorMedix Inc.'>CRMD</a> <font color='green'>+24.9%</font>) is up on more than triple normal volume as it resumes its momentum that began in late July when it <a href=\"https://www.sec.gov/Archives/edgar/data/1410098/000165495418008007/crmd_ex991.htm\" target=\"_blank\">announced </a>the early termination of its Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02651428?lead=cormedix&amp;phase=2&amp;rank=1\" target=\"_blank\">LOCK-IT-100</a>, evaluating the effect of Neutrolin (taurolidine) on preventing bloodstream infections in patients receiving peripherally inserted central catheters. The study was stopped for efficacy. The company is in the process of submitting the interim data to the FDA.</li><li>Shares have rallied almost five-fold since then.</li><li>On the working capital front, at the end of June, it had $4.7M in cash and equivalents while operations consumed $11.4M in H1.</li></ul><div class=\"tiny-share-widget\" data-id=\"3394164\" data-linked=\"CorMedix resumes Neutrolin-stoked upward march, shares ahead 25%\" data-tweet=\"$CRMD - CorMedix resumes Neutrolin-stoked upward march, shares ahead 25% https://seekingalpha.com/news/3394164-cormedix-resumes-neutrolin-stoked-upward-march-shares-ahead-25?source=tweet\" data-url=\"https://seekingalpha.com/news/3394164-cormedix-resumes-neutrolin-stoked-upward-march-shares-ahead-25\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394288\" data-ts=\"1538413808\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNGA\" target=\"_blank\">MNGA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394288-magnegas-launches-rebranding-alongside-european-market-expansion\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MagneGas launches rebranding alongside European market expansion</a></h4><ul>     <li>MagneGas (<a href='https://seekingalpha.com/symbol/MNGA' title='MagneGas Corporation'>MNGA</a> <font color='green'>+16.7%</font>) moves higher by as much as 35% after saying it has <a href=\"https://seekingalpha.com/pr/17285707-magnegas-implements-corporate-rebranding\" target=\"_blank\">rebranded itself</a> as MagneGas Applied Technology Solutions.</li>     <li>MNGA says the new name better reflects the commercial uses for its submerged plasma-arc technology, which include synthetic gas for industrial metal-cutting in addition to sterilizing agricultural waste and waste-to-energy applications.</li>     <li>MNGA says it initiated the rebranding in conjunction with its accelerating marketing efforts in Europe.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3394288\" data-linked=\"MagneGas launches rebranding alongside European market expansion\" data-tweet=\"$MNGA $TRNX - MagneGas launches rebranding alongside European market expansion https://seekingalpha.com/news/3394288-magnegas-launches-rebranding-alongside-european-market-expansion?source=tweet\" data-url=\"https://seekingalpha.com/news/3394288-magnegas-launches-rebranding-alongside-european-market-expansion\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394160\" data-ts=\"1538413438\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATLC\" target=\"_blank\">ATLC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394160-financials-top-5-gainers-losers-of-1-03-pm-10-01-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:03 PM (10/01/2018)</a></h4><ul><li><b>Gainers:&nbsp;</b><a href='https://seekingalpha.com/symbol/ATLC' title='Atlanticus Holdings Corp.'>ATLC</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/JTPY' title='JetPay Corporation'>JTPY</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/EVER' title='EverQuote'>EVER</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/FANH' title='Fanhua Inc.'>FANH</a> <font color='green'>+5%</font>.</li><li><b>Losers: </b><a href='https://seekingalpha.com/symbol/PMTS' title='CPI Card Group'>PMTS</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/TRUP' title='Trupanion'>TRUP</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/EXPI' title='eXp World Holdings, Inc.'>EXPI</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/KFS' title='Kingsway Financial Services Inc'>KFS</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/MLVF' title='Malvern Federal Bancorp, Inc.'>MLVF</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3394160\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:03 PM (10/01/2018)\" data-tweet=\"$ATLC $ATLC $JTPY - Financials - Top 5 Gainers / Losers as of 1:03 PM (10/01/2018) https://seekingalpha.com/news/3394160-financials-top-5-gainers-losers-of-1-03-pm-10-01-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3394160-financials-top-5-gainers-losers-of-1-03-pm-10-01-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394158\" data-ts=\"1538413270\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IGC\" target=\"_blank\">IGC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394158-india-globalization-capital-enters-15m-common-stock-market-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">India Globalization Capital enters into $15M common stock At-the-Market Offering</a></h4><ul>     <li>India Globalization Capital (<a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a> <font color='green'>+22.9%</font>) enters into $15M common stock At-the-Market Offering Agreement with The Benchmark Company and ViewTrade Securities.</li><li><a href=\"https://www.sec.gov/Archives/edgar/data/1326205/000118518518001776/ex_124811.htm\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3394158\" data-linked=\"India Globalization Capital enters into $15M common stock At-the-Market Offering\" data-tweet=\"$IGC - India Globalization Capital enters into $15M common stock At-the-Market Offering https://seekingalpha.com/news/3394158-india-globalization-capital-enters-15m-common-stock-market-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3394158-india-globalization-capital-enters-15m-common-stock-market-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394157\" data-ts=\"1538413167\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCBFF\" target=\"_blank\">SCBFF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394157-stanchart-sinks-after-1_5b-figure-said-to-emerge-for-potential-iran-fine\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">StanChart sinks after $1.5B figure said to emerge for potential Iran fine</a></h4><ul><li>Standard Chartered (<a href='https://seekingalpha.com/symbol/SCBFF' title='Standard Chartered PLC'>OTCPK:SCBFF</a>)<font color='red'> drops 4.5%</font>&nbsp;after Bloomberg reports that the bank <a href=\"https://www.bloomberg.com/news/articles/2018-10-01/stanchart-said-to-brace-for-new-iran-fine-of-about-1-5-billion?cmpid=socialflow-twitter-business&amp;utm_campaign=socialflow-organic&amp;utm_medium=social&amp;utm_content=business&amp;utm_source=twitter\" target=\"_blank\">is bracing </a>for a potential fine of about $1.5B from U.S. regulators for allowing its clients to violate Iran sanctions, according to people familiar with the matter.</li><li>The preliminary figure comes from some communications between the bank and regulators; final talks to resolve the matter haven't started yet.</li><li>The alleged violations date from at least five years ago. As disclosed earlier this year, the authorities are investigating whether \"conduct and control failures\" allowed clients with Iranian interests to execute transactions through Standard Chartered Bank after 2007 and the \"extent to which any such failures were shared\" with U.S. authorities in 2012, according to a company filing.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386346-standard-chartered-may-face-another-fine\" target=\"_blank\">Standard Chartered may face another fine</a> (Aug. 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3394157\" data-linked=\"StanChart sinks after $1.5B figure said to emerge for potential Iran fine\" data-tweet=\"$SCBFF - StanChart sinks after $1.5B figure said to emerge for potential Iran fine https://seekingalpha.com/news/3394157-stanchart-sinks-after-1_5b-figure-said-to-emerge-for-potential-iran-fine?source=tweet\" data-url=\"https://seekingalpha.com/news/3394157-stanchart-sinks-after-1_5b-figure-said-to-emerge-for-potential-iran-fine\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394153\" data-ts=\"1538412566\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EUTLY\" target=\"_blank\">EUTLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394153-european-satellite-firms-form-mid-band-clearinghouse\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European satellite firms form mid-band clearinghouse</a></h4><ul>   <li>European satellite operators are higher today in U.S. trading after <a href=\"https://seekingalpha.com/pr/17285360-intelsat-ses-eutelsat-telesat-establish-c-band-alliance-cba-consortium-facilitate-clearing-u\" target=\"_blank\">establishing a clearinghouse</a> to help redistribute mid-band spectrum for 5G use.</li>    <li>Intelsat (<a href=\"http://seekingalpha.com/symbol/I\" target=\"_blank\">I</a> <font color='green'>+1.4%</font>), Eutelsat (<a href='https://seekingalpha.com/symbol/EUTLY' title='Eutelsat Communications ADR'>OTCPK:EUTLY</a>), SES (<a href=\"http://seekingalpha.com/symbol/SGBAF\" target=\"_blank\">SGBAF</a> <font color='green'>+2.7%</font>) and Telesat (principal shareholder <a href='https://seekingalpha.com/symbol/LORL' title='Loral Space and Communications, Inc.'>LORL</a> is <font color='green'>up 2.4%</font>) have formed the C-Band Alliance, the latest in a series of moves that look to exploit those satellite frequencies for use in the wide deployment of 5G without hurting existing use cases.</li>    <li>The CBA's intended to act as a facilitator, a role described in recent FCC proceedings around mid-band redeployment.</li><li>It's planned to implement market-based transactions to clear the spectrum from 3.7 GHz to 4.2 GHz.</li>    <li>A push for mid-band redeployment has been led this year by Intelsat, SES and Intel (<a href=\"http://seekingalpha.com/symbol/INTC\" target=\"_blank\">INTC</a> <font color='red'>-1.6%</font>).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3394153\" data-linked=\"European satellite firms form mid-band clearinghouse\" data-tweet=\"$EUTLY $EUTLY $LORL - European satellite firms form mid-band clearinghouse https://seekingalpha.com/news/3394153-european-satellite-firms-form-mid-band-clearinghouse?source=tweet\" data-url=\"https://seekingalpha.com/news/3394153-european-satellite-firms-form-mid-band-clearinghouse\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394154\" data-ts=\"1538412566\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394154-geplus-10-after-luring-all-star-ceo-turnaround-will-be-tough\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE +10% after luring all-star CEO, but turnaround will be tough</a></h4><ul>     <li>General Electric (<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a> <font color='green'>+9.6%</font>) jumped as much as 16% after naming highly respected former Danaher CEO&nbsp;Larry Culp is its <a href=\"https://seekingalpha.com/news/3393947-ge-replaces-ceo-shares-8-percent\" target=\"_blank\">new boss</a>, as the move is <a href=\"https://finance.yahoo.com/news/ge-investors-happy-ceo-analysts-153222994.html\" target=\"_blank\">broadly supported by analysts</a> - although no one has upgraded the stock - but Culp has a <a href=\"https://www.barrons.com/articles/new-ge-ceo-larry-culp-has-a-tough-hand-to-play-1538408535\" target=\"_blank\">tough hand to play</a> - growing problems at the power business, the separation of GE's health care business by year-end 2019, the company's heavy debt load, etc.</li>     <li>GE also is withdrawing prior financial guidance for 2018, including projections for free cash flow and earnings per share, due to a $23B writedown in its power business, which will affect GE&rsquo;s long-term profitability.</li>     <li><a href=\"https://www.wsj.com/articles/new-ge-old-problems-1538405385\" target=\"_blank\">The short term is more worrisome</a>, says <em>WSJ</em>'s Spencer Jakab; free cash flow guidance for 2018 was abandoned with no new figure forthcoming until at least Q3 results later this month, which is \"especially alarming as GE has pulled nearly all the levers it had at its disposal to shore up its balance sheet.\"</li>     <li>UBS analyst Steven Winoker, who has a Neutral rating and price target of $13 on the stock, says the news sets &ldquo;the stage for re-baselining the company, dividend policy and capital-deployment again.&rdquo;</li>     <li>\"Under Culp, investors may be willing to look further out to assess what GE may be worth post the planned portfolio moves,\" says Cowen's Gautam Khanna, who rates the stock at Market Perform with a $14.50 price target.</li>     <li>&ldquo;We see GE taking additional steps to protect its credit rating due to lower Power profitability and cash flow. We see a significant cut to dividend earlier than previously expected,&rdquo; says BofA&nbsp;Merrill Lynch, which also rates the stock as Neutral.</li>     <li>Longtime GE bear Stephen Tusa at J.P. Morgan sees the timing and format of the CEO change  announcement as a negative surprise that raises questions as to whether there are \"serious issues at play,\" noting details on how bad things actually are have not been shared; he maintains his Underweight rating and $10 price target.</li></ul><div class=\"tiny-share-widget\" data-id=\"3394154\" data-linked=\"GE +10% after luring all-star CEO, but turnaround will be tough\" data-tweet=\"$GE - GE +10% after luring all-star CEO, but turnaround will be tough https://seekingalpha.com/news/3394154-geplus-10-after-luring-all-star-ceo-turnaround-will-be-tough?source=tweet\" data-url=\"https://seekingalpha.com/news/3394154-geplus-10-after-luring-all-star-ceo-turnaround-will-be-tough\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394152\" data-ts=\"1538412407\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PMCB\" target=\"_blank\">PMCB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394152-pharmacyte-bio-up-8-on-advancement-toward-clinical-study-of-novel-cancer-treatment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PharmaCyte Bio up 8% on advancement toward clinical study of novel cancer treatment</a></h4><ul><li>Nano cap PharmaCyte Biotech (<a href='https://seekingalpha.com/symbol/PMCB' title='PharmaCyte Biotech, Inc.'>OTCQB:PMCB</a> <font color='green'>+7.5%</font>) in up on more than triple normal volume in response to its <a href=\"https://seekingalpha.com/pr/17286157-pharmacyte-biotech-reports-completion-crucial-fda-required-study-pancreatic-cancer-trial\" target=\"_blank\">announcement </a>that has satisfied another FDA requirement for its planned clinical trial evaluating 22P1G, genetically altered human cells, together with the cancer prodrug ifosfamide.</li><li>Specifically, the company identified the modified site and chromosome location of the gene that codes for the enzyme that activates the anti-tumor effect of ifosfamide.</li><li>The company says the value-add of its targeted cancer therapy is the ability to deliver comparable chemo efficacy at 1/3 the dose. It accomplishes this by implanting the encapsulated cells close to the tumor where they act as a \"bio-artificial liver\" bypassing the normal activation of the drug in that organ.</li></ul><div class=\"tiny-share-widget\" data-id=\"3394152\" data-linked=\"PharmaCyte Bio up 8% on advancement toward clinical study of novel cancer treatment\" data-tweet=\"$PMCB - PharmaCyte Bio up 8% on advancement toward clinical study of novel cancer treatment https://seekingalpha.com/news/3394152-pharmacyte-bio-up-8-on-advancement-toward-clinical-study-of-novel-cancer-treatment?source=tweet\" data-url=\"https://seekingalpha.com/news/3394152-pharmacyte-bio-up-8-on-advancement-toward-clinical-study-of-novel-cancer-treatment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394151\" data-ts=\"1538412008\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OGEN\" target=\"_blank\">OGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394151-midday-gainers-losers-10-01-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (10/01/2018)</a></h4><ul>     <li><strong>Gainers:</strong> <a href='https://seekingalpha.com/symbol/OGEN' title='Oragenics, Inc.'>OGEN</a> <font color='green'>+51%</font>. <a href='https://seekingalpha.com/symbol/LEVB' title='Level Brands, Inc.'>LEVB</a> <font color='green'>+37%</font>. <a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='green'>+39%</font>. <a href='https://seekingalpha.com/symbol/ARCW' title='ARC Group Worldwide, Inc.'>ARCW</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/NTGN' title='Neon Therapeutics'>NTGN</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/IFMK' title='iFresh Inc.'>IFMK</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/ACST' title='Acasti Pharma, Inc.'>ACST</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/ATLC' title='Atlanticus Holdings Corp.'>ATLC</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/ALT' title='Altimmune, Inc.'>ALT</a> <font color='green'>+21%</font>.</li>      <li><strong>Losers:</strong> <a href='https://seekingalpha.com/symbol/AKRX' title='Akorn, Inc.'>AKRX</a> <font color='red'>-55%</font>. RXII <font color='red'>-48%</font>. <a href='https://seekingalpha.com/symbol/AVRO' title='AVROBIO'>AVRO</a> <font color='red'>-44%</font>. <a href='https://seekingalpha.com/symbol/SERV' title='ServiceMaster Global'>SERV</a> <font color='red'>-35%</font>. <a href='https://seekingalpha.com/symbol/CSBR' title='Champions Oncology, Inc.'>CSBR</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/INFN' title='Infinera Corporation'>INFN</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/INSM' title='Insmed, Inc.'>INSM</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/LFIN' title='LongFin Corp.A'>OTCPK:LFIN</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/RYAAY' title='Ryanair Holdings PLC'>RYAAY</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/ACHV' title='Achieve Life Sciences, Inc.'>ACHV</a> <font color='red'>-15%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3394151\" data-linked=\"Midday Gainers / Losers (10/01/2018)\" data-tweet=\"$OGEN $OGEN $YCBD - Midday Gainers / Losers (10/01/2018) https://seekingalpha.com/news/3394151-midday-gainers-losers-10-01-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3394151-midday-gainers-losers-10-01-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394149\" data-ts=\"1538411670\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROKU\" target=\"_blank\">ROKU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394149-rokuplus-3_7-new-high-price-target-from-cannonball\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Roku +3.7% with new high price target from Cannonball</a></h4><ul>   <li>Roku (NASDAQ:<a href='https://seekingalpha.com/symbol/ROKU' title='Roku Inc.'>ROKU</a>) is <font color='green'>up 3.7%</font> following this morning's <a href=\"https://seekingalpha.com/news/3394000-roku-gains-target-boost-16-percent-upside\" target=\"_blank\">price target hike</a> from Needham and a lift to a new Street-high target from Cannonball Research.</li>    <li>Cannonball chief Vasily Karasyov has set the new topper with a target of $97, up from $68 and implying 28% from today's now-higher price.</li>    <li>Karasyov expects ad revenues to nearly double this year to $300M, with about 80% of that coming from a ramp up in ad-supported streaming time. Ad-supported hours now make up 41% of inventory, Karasyov estimates, up from a year-ago 36%. (h/t Bloomberg)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3394149\" data-linked=\"Roku +3.7% with new high price target from Cannonball\" data-tweet=\"$ROKU - Roku +3.7% with new high price target from Cannonball https://seekingalpha.com/news/3394149-rokuplus-3_7-new-high-price-target-from-cannonball?source=tweet\" data-url=\"https://seekingalpha.com/news/3394149-rokuplus-3_7-new-high-price-target-from-cannonball\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394143\" data-ts=\"1538410685\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BSEM\" target=\"_blank\">BSEM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394143-biostem-launches-four-amniotic-products-investors-unmoved-shares-down-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioStem launches four amniotic products; investors unmoved, shares down 9%</a></h4><ul><li>Ultra-thinly traded BioStem Technologies (<a href='https://seekingalpha.com/symbol/BSEM' title='BioStem Technologies, Inc.'>OTCPK:BSEM</a> <font color='red'>-8.5%</font>) is down on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/17286371-biostem-life-sciences-inc-subsidiary-biostem-technologies-inc-announces-entry-market-four\" target=\"_blank\">announcement </a>that subsidiary BioStem Life Sciences is rolling out four new placental-derived products for a range of indications.</li><li>The products are an amniotic tissue allograft flowable matrix, a chorion-free amniotic tissue allograft membrane, an amniotic tissue allograft membrane with chorion layer, and an extracellular&nbsp;amniotic membrane&nbsp;allograft for ocular repair.</li><li>The company says the amniotic tissue market is over $800M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3394143\" data-linked=\"BioStem launches four amniotic products; investors unmoved, shares down 9%\" data-tweet=\"$BSEM - BioStem launches four amniotic products; investors unmoved, shares down 9% https://seekingalpha.com/news/3394143-biostem-launches-four-amniotic-products-investors-unmoved-shares-down-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3394143-biostem-launches-four-amniotic-products-investors-unmoved-shares-down-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:18 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394138\" data-ts=\"1538409990\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EAPH\" target=\"_blank\">EAPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394138-easton-pharma-up-18-on-prospects-of-investment-in-greek-casino-resort\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Easton Pharma up 18% on prospects of investment in Greek casino &amp; resort</a></h4><ul><li>Nano cap Easton Pharmaceuticals (<a href='https://seekingalpha.com/symbol/EAPH' title='Easton Pharmaceuticals, Inc.'>OTCPK:EAPH</a> <font color='green'>+17.6%</font>) is up on average volume in apparent response to its <a href=\"https://seekingalpha.com/pr/17286454-easton-pharmaceuticals-short-listed-acquire-interest-operating-casino-hotel-resort-loutraki\" target=\"_blank\">announcement </a>that it is on the \"short list\" to acquire an interest in a Greek casino and resort called Club Hotel Casino Loutraki. It first announced the potential deal in August.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3384803-easton-pharma-eyeing-stake-greek-hotel-casino\" target=\"_blank\">Easton Pharma eyeing stake on Greek hotel and casino</a> (Aug. 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3394138\" data-linked=\"Easton Pharma up 18% on prospects of investment in Greek casino &amp; resort\" data-tweet=\"$EAPH - Easton Pharma up 18% on prospects of investment in Greek casino &amp; resort https://seekingalpha.com/news/3394138-easton-pharma-up-18-on-prospects-of-investment-in-greek-casino-resort?source=tweet\" data-url=\"https://seekingalpha.com/news/3394138-easton-pharma-up-18-on-prospects-of-investment-in-greek-casino-resort\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394133\" data-ts=\"1538409661\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBEV\" target=\"_blank\">NBEV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394133-consumer-top-5-gainers-losers-of-12-00-pm-10-01-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top 5 Gainers / Losers as of 12:00 PM (10/01/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='green'>+33%</font>. <a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/YGYI' title='Youngevity International, Inc.'>YGYI</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/SANW' title='S&W Seed Co'>SANW</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/CLAR' title='Clarus Corporation'>CLAR</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SONO' title='Sonos, Inc.'>SONO</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/REVG' title='REV Group'>REVG</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/CALM' title='Cal-Maine Foods, Inc.'>CALM</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/FORK' title='Fuling Global'>FORK</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/FNKO' title='Funko, Inc.'>FNKO</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3394133\" data-linked=\"Consumer - Top 5 Gainers / Losers as of 12:00 PM (10/01/2018)\" data-tweet=\"$NBEV $NBEV $TSLA - Consumer - Top 5 Gainers / Losers as of 12:00 PM (10/01/2018) https://seekingalpha.com/news/3394133-consumer-top-5-gainers-losers-of-12-00-pm-10-01-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3394133-consumer-top-5-gainers-losers-of-12-00-pm-10-01-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394127\" data-ts=\"1538408733\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXP\" target=\"_blank\">AXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394127-wells-fargo-raises-price-targets-on-five-credit-card-stocks-on-q3-optimism\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wells Fargo raises price targets on five credit card stocks on Q3 optimism</a></h4><ul><li>Wells Fargo analyst Donald Fandetti boosts price targets for American Express (<a href='https://seekingalpha.com/symbol/AXP' title='American Express Company'>AXP</a> <font color='green'>+1.8%</font>), Capital One (<a href='https://seekingalpha.com/symbol/COF' title='Capital One Financial Corporation'>COF</a> <font color='green'>+0.5%</font>), Discover Financial (<a href='https://seekingalpha.com/symbol/DFS' title='Discover Financial Services'>DFS</a> <font color='green'>+0.6%</font>), Mastercard (<a href='https://seekingalpha.com/symbol/MA' title='Mastercard, Inc.'>MA</a> <font color='green'>+0.8%</font>), and Visa (<a href='https://seekingalpha.com/symbol/V' title='Visa Inc.'>V</a> <font color='green'>+0.9%</font>) as a stronger-than-expected U.S. consumer combined with easing credit pressure are set to fuel Q3 results.</li><li>AXP price target increased to $122 from $115; COF to $110 from $109; DFS to $82 from $76, MA to $250 from $230, and V to $175 from $161.</li><li>He sees V, MA,&nbsp; COF, and Synchrony Financial (<a href='https://seekingalpha.com/symbol/SYF' title='Synchrony Financial'>SYF</a> <font color='green'>+1.2%</font>) as likely to beat consensus with AXP and DFS being in line; still a bias toward upside.</li><li>There's more potential for COF to buy the $10b Walmart portfolio from SYF, instead of SYF keeping the loan book, he says.</li><li>Source: Bloomberg First Word.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3390800-american-express-reports-august-delinquency-write-rate\" target=\"_blank\">American Express reports August delinquency and write-off rate</a> (Sept. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3394127\" data-linked=\"Wells Fargo raises price targets on five credit card stocks on Q3 optimism\" data-tweet=\"$AXP $AXP $COF - Wells Fargo raises price targets on five credit card stocks on Q3 optimism https://seekingalpha.com/news/3394127-wells-fargo-raises-price-targets-on-five-credit-card-stocks-on-q3-optimism?source=tweet\" data-url=\"https://seekingalpha.com/news/3394127-wells-fargo-raises-price-targets-on-five-credit-card-stocks-on-q3-optimism\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394117\" data-ts=\"1538407272\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ON\" target=\"_blank\">ON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394117-on-semiconductor-increases-stake-in-8-inch-wafer-fab\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ON Semiconductor increases stake in 8-inch wafer fab</a></h4><ul><li>        ON Semiconductor (NASDAQ:<a href='https://seekingalpha.com/symbol/ON' title='ON Semiconductor Corporation'>ON</a>) <a href=\"https://seekingalpha.com/pr/17285291-semiconductor-completes-additional-share-purchase-fujitsu-s-8-inch-wafer-fab\" target=\"_blank\">completes</a> its incremental 20% share purchase of Aizu Fujitsu Semiconductor Manufacturing, Fujitsu&rsquo;s 8-inch wafer fab.</li><li>               The investment brings ON up to a 60% majority ownership in the joint venture, up from the 10% it held at the JV&rsquo;s founding in 2014. ON will increase its ownership to 100% by 1H20.&nbsp;</li><li>        The added capacity will help ON meet forecasted demand and provide supply chain flexibility.&nbsp;</li><li>               After today&rsquo;s transaction closing, the wafer fab will be renamed ON Semiconductor Aizu Co.&nbsp;</li><li>                  ON shares are&nbsp;<font color='green'>up 1.6%</font>&nbsp;to $18.72.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3394117\" data-linked=\"ON Semiconductor increases stake in 8-inch wafer fab\" data-tweet=\"$ON - ON Semiconductor increases stake in 8-inch wafer fab https://seekingalpha.com/news/3394117-on-semiconductor-increases-stake-in-8-inch-wafer-fab?source=tweet\" data-url=\"https://seekingalpha.com/news/3394117-on-semiconductor-increases-stake-in-8-inch-wafer-fab\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394116\" data-ts=\"1538407136\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WLDFF\" target=\"_blank\">WLDFF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394116-wildflower-signs-mou-to-enter-la-delivery-market\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wildflower signs MOU to enter LA delivery market</a></h4><ul>     <li>Wildflower Brands (<a href='https://seekingalpha.com/symbol/WLDFF' title='Wildflower Brands Inc.'>OTCQB:WLDFF</a> <font color='green'>+13.8%</font>) says that the company have received a MOU with one of the leading cannabis delivery technology companies in California.</li>     <li>The company intends to service the western part of the Los Angeles area.</li><li><a href=\"https://seekingalpha.com/pr/17286234-wildflower-signs-mou-enter-la-delivery-market\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3394116\" data-linked=\"Wildflower signs MOU to enter LA delivery market\" data-tweet=\"$WLDFF - Wildflower signs MOU to enter LA delivery market https://seekingalpha.com/news/3394116-wildflower-signs-mou-to-enter-la-delivery-market?source=tweet\" data-url=\"https://seekingalpha.com/news/3394116-wildflower-signs-mou-to-enter-la-delivery-market\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394115\" data-ts=\"1538407057\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MS\" target=\"_blank\">MS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394115-banks-climb-after-goldman-analyst-sees-promising-q3-reports-ahead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Banks climb after Goldman analyst sees promising Q3 reports ahead</a></h4><ul><li>Morgan Stanley (<a href='https://seekingalpha.com/symbol/MS' title='Morgan Stanley'>MS</a> <font color='green'>+0.9%</font>), JPMorgan (<a href='https://seekingalpha.com/symbol/JPM' title='JPMorgan Chase & Co.'>JPM</a> <font color='green'>+0.9%</font>), and Bank of America (<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a> <font color='green'>+0.8%</font>) all gain after Goldman's Richard Ramsden sees potential for them to beat consensus when they report Q3 earnings later this month.</li><li>Overall, he sees big bank stocks attractive after underperforming the broader market. Current profitability may reach a post-crisis high, while macroeconomic concerns are already baked into shares, he says.</li><li>Ramsden also sees momentum on industry loan growth moving into Q4 as Y/Y, rising about 20 basis points in September compared with the rest of the Q3.</li><li>Citigroup (<a href='https://seekingalpha.com/symbol/C' title='Citigroup Inc.'>C</a> <font color='green'>+0.8%</font>), US Bancorp (<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a> <font color='green'>+0.8%</font>), and PNC Financial (<a href='https://seekingalpha.com/symbol/PNC' title='PNC Financial Services Group, Inc.'>PNC</a> <font color='green'>+0.4%</font>) results are expected to be more in line, he says.</li><li>Separately, M&amp;T Bank (<a href='https://seekingalpha.com/symbol/MTB' title='M&T Bank Corporation'>MTB</a> <font color='green'>+0.5%</font>) raised to outperform from in-line by Evercore ISI's John Pancari, as its recent dip provides a buying opportunity.</li><li>Source: Bloomberg First Word.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3393910-u-s-stock-markets-poised-gain-canada-u-s-strike-trade-deal\" target=\"_blank\">U.S. stock markets poised to gain as Canada-U.S. strike trade deal</a> (Oct. 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3394115\" data-linked=\"Banks climb after Goldman analyst sees promising Q3 reports ahead\" data-tweet=\"$MS $MS $JPM - Banks climb after Goldman analyst sees promising Q3 reports ahead https://seekingalpha.com/news/3394115-banks-climb-after-goldman-analyst-sees-promising-q3-reports-ahead?source=tweet\" data-url=\"https://seekingalpha.com/news/3394115-banks-climb-after-goldman-analyst-sees-promising-q3-reports-ahead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394114\" data-ts=\"1538406525\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIMX\" target=\"_blank\">HIMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394114-himaxplus-4_8-roth-says-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Himax +4.8% as Roth says Buy</a></h4><ul><li>        Roth Capital <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Roth+Capital+Upgrades+Himax+Technologies+%28HIMX%29+to+Buy/14659602.html\" target=\"_blank\">upgrades</a> Himax (NASDAQ:<a href='https://seekingalpha.com/symbol/HIMX' title='Himax Technologies, Inc.'>HIMX</a>) from Neutral to Buy with a $7 price target, a 19% upside to Friday&rsquo;s close.</li><li>               The company&rsquo;s next earnings report is expected on November 8. The Q2 report in August missed on revenue but met on EPS. The downside Q3 forecast included revenue at about $162.85M (consensus: $209.1M) and EPS of $0.015 (consensus: $0.03).&nbsp;</li><li>               Himax shares are&nbsp;<font color='green'>up 4.8%</font>&nbsp;to $6.16. Shares have dropped&nbsp;<font color='red'>nearly 10%</font>&nbsp;in the past month,&nbsp;<font color='red'>21%</font>&nbsp;in the quarter, and&nbsp;<font color='red'>43.5%</font>&nbsp;YTD.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3380745-himax-technologies-eps-line-misses-revenue\" target=\"_blank\">Himax Technologies EPS in-line, misses on revenue</a> (Aug. 9)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3380932-himax-reports-mixed-q2-downside-guidance\" target=\"_blank\">Himax reports mixed Q2, downside guidance</a> (Aug. 9)</li></ul><div class=\"tiny-share-widget\" data-id=\"3394114\" data-linked=\"Himax +4.8% as Roth says Buy\" data-tweet=\"$HIMX - Himax +4.8% as Roth says Buy https://seekingalpha.com/news/3394114-himaxplus-4_8-roth-says-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3394114-himaxplus-4_8-roth-says-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394109\" data-ts=\"1538406249\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OGEN\" target=\"_blank\">OGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394109-oragenics-adds-to-rally-up-46\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oragenics adds to rally, up 46%</a></h4><ul><li>Thinly traded micro cap Oragenics (<a href='https://seekingalpha.com/symbol/OGEN' title='Oragenics, Inc.'>OGEN</a> <font color='green'>+46.1%</font>) is up on below-average volume. Shares have quadrupled since mid-September.</li><li>On September 24, a company executive <a href=\"https://www.sec.gov/Archives/edgar/data/1174940/000119312518282624/d605722d8k.htm\" target=\"_blank\">delivered </a>a <a href=\"https://www.sec.gov/Archives/edgar/data/1174940/000119312518282624/d605722dex991.htm\" target=\"_blank\">presentation </a>on its lanthipeptide antibiotics in <em>C. diff</em>-associated disease at the Boulder Peptide Symposium.</li><li>Preliminary data on lead <em>C. diff</em> candidate OG716 showed no cross-reactivity with existing classes of antibiotics and minimal in vitro cytotoxicity and immunogenicity in cell models.</li></ul><div class=\"tiny-share-widget\" data-id=\"3394109\" data-linked=\"Oragenics adds to rally, up 46%\" data-tweet=\"$OGEN - Oragenics adds to rally, up 46% https://seekingalpha.com/news/3394109-oragenics-adds-to-rally-up-46?source=tweet\" data-url=\"https://seekingalpha.com/news/3394109-oragenics-adds-to-rally-up-46\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394108\" data-ts=\"1538406072\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INSE\" target=\"_blank\">INSE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394108-big-jump-for-inspired-entertainment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Big jump for Inspired Entertainment</a></h4><ul> <li>Shares of Inspired Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/INSE' title='Inspired Entertainment, Inc.'>INSE</a>) <font color='green'>shoot up 13%</font> after Craig-Hallum initiates coverage on the microcap stock with a Buy rating.</li> <li>Craig-Hallum's price target of $12 on INSE gives shares plenty of room to run still.</li><li>The 52-week high on Inspired Entertainment is $14.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3394108\" data-linked=\"Big jump for Inspired Entertainment\" data-tweet=\"$INSE - Big jump for Inspired Entertainment https://seekingalpha.com/news/3394108-big-jump-for-inspired-entertainment?source=tweet\" data-url=\"https://seekingalpha.com/news/3394108-big-jump-for-inspired-entertainment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394105\" data-ts=\"1538406067\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OGEN\" target=\"_blank\">OGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394105-healthcare-top-5-gainers-losers-of-11-00-10-01-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 AM (10/01/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/OGEN' title='Oragenics, Inc.'>OGEN</a> <font color='green'>+37%</font>. <a href='https://seekingalpha.com/symbol/SYN' title='Synthetic Biologics, Inc.'>SYN</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/ACST' title='Acasti Pharma, Inc.'>ACST</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/ALT' title='Altimmune, Inc.'>ALT</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/VNRX' title='VolitionRX Ltd'>VNRX</a> <font color='green'>+14%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AKRX' title='Akorn, Inc.'>AKRX</a> <font color='red'>-54%</font>. RXII <font color='red'>-49%</font>. <a href='https://seekingalpha.com/symbol/AVRO' title='AVROBIO'>AVRO</a> <font color='red'>-42%</font>. <a href='https://seekingalpha.com/symbol/INSM' title='Insmed, Inc.'>INSM</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/CSBR' title='Champions Oncology, Inc.'>CSBR</a> <font color='red'>-16%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3394105\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 AM (10/01/2018)\" data-tweet=\"$OGEN $OGEN $SYN - Healthcare - Top 5 Gainers / Losers as of 11:00 AM (10/01/2018) https://seekingalpha.com/news/3394105-healthcare-top-5-gainers-losers-of-11-00-10-01-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3394105-healthcare-top-5-gainers-losers-of-11-00-10-01-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394102\" data-ts=\"1538405522\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOJA\" target=\"_blank\">BOJA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394102-bojanglesplus-7-on-takeover-buzz\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bojangles +7% on takeover buzz</a></h4><ul><li>Bojangles (NASDAQ:<a href='https://seekingalpha.com/symbol/BOJA' title='Bojangles&#39;'>BOJA</a>) is&nbsp;<font color='green'>up 6.6%</font>&nbsp;to follow up on a late double-digit spike Friday off a report the company is exploring strategic options.</li><li>Cowen thinks the restaurant operator could be worth as much as $24 per share in a takeover scenario.</li><li>Shares of BOJA carved out a new 52-week high of $16.90 earlier in today's session.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3393810-bojangles-exploring-sale-reuters-shares-rise-11-percent\" target=\"_blank\">Bojangles exploring sale - Reuters; shares rise 11%</a> (Sept. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3394102\" data-linked=\"Bojangles +7% on takeover buzz\" data-tweet=\"$BOJA - Bojangles +7% on takeover buzz https://seekingalpha.com/news/3394102-bojanglesplus-7-on-takeover-buzz?source=tweet\" data-url=\"https://seekingalpha.com/news/3394102-bojanglesplus-7-on-takeover-buzz\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394099\" data-ts=\"1538405278\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394099-piper-survey-shows-higher-iphone-xs-demand-raises-fy19-asp-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Piper survey shows higher iPhone XS demand, raises FY19 ASP target</a></h4><ul><li>A Piper Jaffray survey of over 700 domestic Apple (<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a> <font color='green'>+1.4%</font>) iPhone owners showed that 39% would upgrade to the iPhone XS or XS Max if they were to upgrade this year with a nearly even split between the models.</li><li>Piper previously assumed only 35% of upgrades would come from the XS/Max.</li><li>The remaining 61% would move to either the forthcoming iPhone XR or existing iPhone 7 or 8. Piper Jaffray expects the XR would take 30% of that group&rsquo;s upgrades.</li><li>The firm raises its FY19 ASP estimate from $758 to $770. If the XR takes more than the 30% of upgrades, the FY19 ASP estimate would hit $780 (consensus: $768) because it costs more than the older models.</li><li>Source: <a href=\"https://9to5mac.com/2018/10/01/iphone-upgraders-iphone-xs/\" target=\"_blank\">9to5Mac</a>/<a href=\"https://www.ped30.com/2018/10/01/50-50-split-apple-iphone/\" target=\"_blank\">PED 3.0</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3393046-report-new-iphone-sales-momentum-likely-slow-late-2018\" target=\"_blank\">Report: New iPhone sales momentum likely to slow in late 2018</a> (Sept. 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3394099\" data-linked=\"Piper survey shows higher iPhone XS demand, raises FY19 ASP target\" data-tweet=\"$AAPL - Piper survey shows higher iPhone XS demand, raises FY19 ASP target https://seekingalpha.com/news/3394099-piper-survey-shows-higher-iphone-xs-demand-raises-fy19-asp-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3394099-piper-survey-shows-higher-iphone-xs-demand-raises-fy19-asp-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394096\" data-ts=\"1538404926\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LEA\" target=\"_blank\">LEA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394096-auto-suppliers-gain-after-u-s-canada-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Auto suppliers gain after U.S.-Canada deal</a></h4><ul> <li>A number of auto parts stocks are ahead of broad market averages after the U.S. and Canada reach a trade deal.</li> <li>Gainers include Lear (<a href='https://seekingalpha.com/symbol/LEA' title='Lear Corporation'>LEA</a> <font color='green'>+3.1%</font>), Meritor (<a href='https://seekingalpha.com/symbol/MTOR' title='Meritor, Inc.'>MTOR</a> <font color='green'>+1%</font>), American Axle &amp; Manufacturing (<a href='https://seekingalpha.com/symbol/AXL' title='American Axle & Manufacturing Holdings, Inc.'>AXL</a> <font color='green'>+1.8%</font>), Gentherm (<a href='https://seekingalpha.com/symbol/THRM' title='Gentherm Incorporated'>THRM</a> <font color='green'>+2.5%</font>), Workhorse Group (<a href='https://seekingalpha.com/symbol/WKHS' title='Workhorse Group Inc.'>WKHS</a> <font color='green'>+1.9%</font>), Superior Industries (<a href='https://seekingalpha.com/symbol/SUP' title='Superior Industries International Inc.'>SUP</a> <font color='green'>+1.7%</font>), Dana (<a href='https://seekingalpha.com/symbol/DAN' title='Dana, Inc.'>DAN</a> <font color='green'>+1.4%</font>) and Westport Fuel Systems (<a href='https://seekingalpha.com/symbol/WKHS' title='Workhorse Group Inc.'>WKHS</a> <font color='green'>+1.9%</font>).</li> <li>The sector has been weighted down by the trade/tariff overhang for most of the year.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3394096\" data-linked=\"Auto suppliers gain after U.S.-Canada deal\" data-tweet=\"$LEA $LEA $MTOR - Auto suppliers gain after U.S.-Canada deal https://seekingalpha.com/news/3394096-auto-suppliers-gain-after-u-s-canada-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3394096-auto-suppliers-gain-after-u-s-canada-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394086\" data-ts=\"1538403729\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INVU\" target=\"_blank\">INVU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394086-investview-repurchases-common-stock\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investview repurchases common stock</a></h4><ul>     <li>Investview Corporation (<a href='https://seekingalpha.com/symbol/INVU' title='Investview Inc.'>OTCQB:INVU</a> <font color='red'>-7.8%</font>) repurchased 7M shares of its previously issued Registered Common Stock in a private transaction, which closed on Sept. 24th, 2018.</li><li><a href=\"https://seekingalpha.com/pr/17286215-belief-buyback-investview-repurchases-common-stock\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3394086\" data-linked=\"Investview repurchases common stock\" data-tweet=\"$INVU - Investview repurchases common stock https://seekingalpha.com/news/3394086-investview-repurchases-common-stock?source=tweet\" data-url=\"https://seekingalpha.com/news/3394086-investview-repurchases-common-stock\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394079\" data-ts=\"1538403034\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APEN\" target=\"_blank\">APEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394079-apollo-endosurgery-completes-enrollment-in-post-approval-study-of-orbera-balloon-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apollo Endosurgery completes enrollment in post-approval study of Orbera balloon; shares up 1%</a></h4><ul><li>Apollo Endosurgery (<a href='https://seekingalpha.com/symbol/APEN' title='Apollo Endosurgery'>APEN</a> <font color='green'>+1.1%</font>) has completed the <a href=\"https://seekingalpha.com/pr/17285633-apollo-endosurgery-completes-enrollment-orbera-post-approval-study\" target=\"_blank\">enrollment </a>of 281 subjects in a post-approval study of its ORBERA intragastric balloon. Objectives include the percentage of total body weight loss at week 26 and week 52 versus baseline (before receiving the balloon) and safety measures. Final data should be available in early 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3394079\" data-linked=\"Apollo Endosurgery completes enrollment in post-approval study of Orbera balloon; shares up 1%\" data-tweet=\"$APEN - Apollo Endosurgery completes enrollment in post-approval study of Orbera balloon; shares up 1% https://seekingalpha.com/news/3394079-apollo-endosurgery-completes-enrollment-in-post-approval-study-of-orbera-balloon-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3394079-apollo-endosurgery-completes-enrollment-in-post-approval-study-of-orbera-balloon-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394075\" data-ts=\"1538402588\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PDCO\" target=\"_blank\">PDCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394075-patterson-to-pay-28_3m-to-settle-antitrust-lawsuit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Patterson to pay $28.3M to settle antitrust lawsuit</a></h4><ul><li>Patterson Companies (<a href='https://seekingalpha.com/symbol/PDCO' title='Patterson Companies Inc.'>PDCO</a> <font color='red'>-0.7%</font>) has <a href=\"https://www.sec.gov/Archives/edgar/data/891024/000119312518287786/d629959d8k.htm\" target=\"_blank\">agreed to pay</a> $28.3M to settle its part in an antitrust lawsuit filed by Benco Dental Supply. Last week, fellow dental products distributor Henry Schein agreed to pay $38.5M to settle its part.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3393858-schein-patterson-benco-settle-antitrust-litigation\" target=\"_blank\">Schein, Patterson and Benco settle antitrust litigation</a> (Sept. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3394075\" data-linked=\"Patterson to pay $28.3M to settle antitrust lawsuit\" data-tweet=\"$PDCO - Patterson to pay $28.3M to settle antitrust lawsuit https://seekingalpha.com/news/3394075-patterson-to-pay-28_3m-to-settle-antitrust-lawsuit?source=tweet\" data-url=\"https://seekingalpha.com/news/3394075-patterson-to-pay-28_3m-to-settle-antitrust-lawsuit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394060\" data-ts=\"1538402045\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DVA\" target=\"_blank\">DVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394060-dialysis-players-in-green-after-veto-of-california-bill-aimed-trimming-premium-assistance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dialysis players in the green after veto of California bill aimed at trimming premium assistance programs</a></h4><ul><li>DaVita (<a href='https://seekingalpha.com/symbol/DVA' title='DaVita HealthCare Partners Inc.'>DVA</a> <font color='green'>+4.2%</font>) and American Renal Associates Holdings (<a href='https://seekingalpha.com/symbol/ARA' title='American Renal Associates Holdings'>ARA</a> <font color='green'>+4.4%</font>) are in the green on the heels of a <a href=\"https://www.gov.ca.gov/wp-content/uploads/2018/09/SB-1156-veto.pdf\" target=\"_blank\">veto </a>by California Governor Jerry Brown of a bill that would have capped premium assistance payments for dialysis patients.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3386758-davita-ara-premarket-looming-ca-bill-curb-dialysis-premium-assistance\" target=\"_blank\">DaVita and ARA down premarket on looming CA bill to curb dialysis premium assistance</a> (Aug. 30)</li></ul><div class=\"tiny-share-widget\" data-id=\"3394060\" data-linked=\"Dialysis players in the green after veto of California bill aimed at trimming premium assistance programs\" data-tweet=\"$DVA $DVA $ARA - Dialysis players in the green after veto of California bill aimed at trimming premium assistance programs https://seekingalpha.com/news/3394060-dialysis-players-in-green-after-veto-of-california-bill-aimed-trimming-premium-assistance?source=tweet\" data-url=\"https://seekingalpha.com/news/3394060-dialysis-players-in-green-after-veto-of-california-bill-aimed-trimming-premium-assistance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394053\" data-ts=\"1538401475\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKTR\" target=\"_blank\">NKTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394053-nektar-down-5-on-bearish-plainview-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nektar down 5% on bearish Plainview report</a></h4><ul><li>Nektar Therapeutics (<a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a> <font color='red'>-4.5%</font>) slips on below-average volume in apparent reaction to a <a href=\"https://s3.amazonaws.com/plainviewllc/Nektar+Therapeutics+Report.pdf\" target=\"_blank\">report </a>from Plainview LLC citing a negative effect on NKTR-214's efficacy from pegylation.</li></ul><div class=\"tiny-share-widget\" data-id=\"3394053\" data-linked=\"Nektar down 5% on bearish Plainview report\" data-tweet=\"$NKTR - Nektar down 5% on bearish Plainview report https://seekingalpha.com/news/3394053-nektar-down-5-on-bearish-plainview-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3394053-nektar-down-5-on-bearish-plainview-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>44&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394038\" data-ts=\"1538400813\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOMX\" target=\"_blank\">FOMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394038-foamix-up-on-positive-late-stage-data-on-acne-candidate-fmx101\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Foamix up on positive late-stage data on acne candidate FMX101</a></h4><ul><li>Foamix Pharmaceuticals (<a href='https://seekingalpha.com/symbol/FOMX' title='Foamix Pharmaceuticals'>FOMX</a> <font color='green'>+0.3%</font>) is up at the open following its <a href=\"https://seekingalpha.com/pr/17285748-foamix-announces-additional-positive-topline-results-third-phase-3-trial-study-fx2017minus-22\" target=\"_blank\">announcement </a>of additional positive topline data from its third Phase 3 clinical trial evaluating topical acne candidate FMX101.</li><li>Treated patients experienced significant reductions in the number of non-inflammatory lesions&nbsp; compared to vehicle (placebo) at weeks 3,6,9 and 12.</li><li>At week 12, 95% of the tolerability scores were 0 (none) or 1 (mild).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3389526-foamix-pharma-plus-54-percent-acne-drug-meets-goals-late-stage-trial\" target=\"_blank\">Foamix Pharma +54% as acne drug meets goals in late-stage trial</a> (Sept. 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3394038\" data-linked=\"Foamix up on positive late-stage data on acne candidate FMX101\" data-tweet=\"$FOMX - Foamix up on positive late-stage data on acne candidate FMX101 https://seekingalpha.com/news/3394038-foamix-up-on-positive-late-stage-data-on-acne-candidate-fmx101?source=tweet\" data-url=\"https://seekingalpha.com/news/3394038-foamix-up-on-positive-late-stage-data-on-acne-candidate-fmx101\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:33 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394033\" data-ts=\"1538400458\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XRF\" target=\"_blank\">XRF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394033-china-rapid-financeminus-2_1-after-regulatory-submission-board-resignation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China Rapid Finance -2.1% after regulatory submission, board resignation</a></h4><ul><li>China Rapid Finance (NYSE:<a href='https://seekingalpha.com/symbol/XRF' title='China Rapid Finance'>XRF</a>)&nbsp;<font color='red'>falls 2.1%</font>&nbsp;in premarket action after it reports <a href=\"https://seekingalpha.com/pr/17285864-china-rapid-finance-announces-submission-regulatory-report-board-change\" target=\"_blank\">submitting </a>its P2P compliance self-inspection report to its local regulatory office and a board resignation.</li><li>The company says it expects to complete by the end of the year the next two process steps for compliance with industry reforms by the National P2P Rectification Office. Those steps are: a self-disciplinary inspection conducted by National Internet Finance Association and regional regulatory authorities; and verification of inspection results by the regional P2P Rectification Office to conduct on field inspections.</li><li>Separately, China Rapid Finance says Andrew Mason resigned from the board for personal reasons.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392686-china-rapid-finance-names-former-hewlett-packard-exec-co-ceo\" target=\"_blank\">China Rapid Finance names former Hewlett Packard exec as co-CEO</a> (Sept. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3394033\" data-linked=\"China Rapid Finance -2.1% after regulatory submission, board resignation\" data-tweet=\"$XRF - China Rapid Finance -2.1% after regulatory submission, board resignation https://seekingalpha.com/news/3394033-china-rapid-financeminus-2_1-after-regulatory-submission-board-resignation?source=tweet\" data-url=\"https://seekingalpha.com/news/3394033-china-rapid-financeminus-2_1-after-regulatory-submission-board-resignation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394032\" data-ts=\"1538400456\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IBM\" target=\"_blank\">IBM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394032-ibm-groupon-settle-patent-fights-grpnplus-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IBM, Groupon settle patent fights; GRPN +2%</a></h4><ul>   <li><a href='https://seekingalpha.com/symbol/IBM' title='International Business Machines Corporation'>IBM</a> and Groupon (NASDAQ:<a href='https://seekingalpha.com/symbol/GRPN' title='Groupon, Inc.'>GRPN</a>) have <a href=\"https://seekingalpha.com/pr/17286166-ibm-groupon-announce-settlement-patent-litigation\" target=\"_blank\">settled all of their patent litigation</a>.</li>    <li>The peace deal involves a payment of about $57M to IBM and a long-term cross-licensing deal between the two.</li>    <li>And IBM will consider making Groupon products and exclusive available to employees through its benefits program.</li>    <li>Premarket, Groupon is <font color='green'>up 2%</font>; <a href='https://seekingalpha.com/symbol/IBM' title='International Business Machines Corporation'>IBM</a> is <font color='green'>up 0.6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3394032\" data-linked=\"IBM, Groupon settle patent fights; GRPN +2%\" data-tweet=\"$IBM $IBM $GRPN - IBM, Groupon settle patent fights; GRPN +2% https://seekingalpha.com/news/3394032-ibm-groupon-settle-patent-fights-grpnplus-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3394032-ibm-groupon-settle-patent-fights-grpnplus-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394030\" data-ts=\"1538400387\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYN\" target=\"_blank\">SYN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394030-premarket-gainers-of-9-05-10-01-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am (10/01/2018)</a></h4><ul><li><a href='https://seekingalpha.com/symbol/SYN' title='Synthetic Biologics, Inc.'>SYN</a> <font color='green'>+52%</font>.</li><li><a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='green'>+27%</font>&nbsp;as volatile trade <a href=\"https://seekingalpha.com/news/3393975-new-ages-beverages-bid-17-percent\" target=\"_blank\">continue</a> in October.</li><li><a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a> <font color='green'>+26%</font>.</li><li><a href='https://seekingalpha.com/symbol/OGEN' title='Oragenics, Inc.'>OGEN</a> <font color='green'>+23%</font>.</li><li><a href='https://seekingalpha.com/symbol/LEVB' title='Level Brands, Inc.'>LEVB</a> <font color='green'>+17%</font>.</li><li><a href='https://seekingalpha.com/symbol/ACST' title='Acasti Pharma, Inc.'>ACST</a> <font color='green'>+16%</font>.</li><li><a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a> <font color='green'>+15%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3393947-ge-replaces-ceo-shares-8-percent\" target=\"_blank\">replacing</a> CEO.</li><li><a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a> <font color='green'>+15%</font>&nbsp;after Musk SEC <a href=\"https://seekingalpha.com/news/3393973-tesla-plus-18-percent-musk-sec-settlement\" target=\"_blank\">settlement</a>.</li><li><a href='https://seekingalpha.com/symbol/ZN' title='Zion Oil & Gas Inc'>ZN</a> <font color='green'>+9%</font>.</li><li><a href='https://seekingalpha.com/symbol/ATRS' title='Antares Pharma Inc.'>ATRS</a> <font color='green'>+10%</font>&nbsp;as FDA <a href=\"https://seekingalpha.com/news/3393945-fda-oks-antares-pharms-trt-med-xyosted\" target=\"_blank\">OKs</a> TRT med Xyosted.</li><li><a href='https://seekingalpha.com/symbol/MGA' title='Magna International Inc.'>MGA</a> <font color='green'>+9%</font>.</li><li><a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a> <font color='green'>+9%</font>&nbsp;as subsidiary High Park Farms <a href=\"https://seekingalpha.com/news/3394002-tilray-subsidiary-high-park-farms-receives-cannabis-sales-license-health-canada\" target=\"_blank\">receives</a> cannabis sales license from Health&nbsp;Canada.</li><li><a href='https://seekingalpha.com/symbol/MTSL' title='MER Telemanagement Solutions Ltd.'>MTSL</a> <font color='green'>+7%</font>.</li><li><a href='https://seekingalpha.com/symbol/INFI' title='Infinity Pharmaceuticals, Inc.'>INFI</a> <font color='green'>+7%</font>&nbsp;on $22M&nbsp;<a href=\"https://seekingalpha.com/pr/17285937-infinity-pharmaceuticals-earns-22-million-payment-verastem-oncology-fda-approval-copiktra\" target=\"_blank\">payment&nbsp;</a>from Verastem Oncology For FDA Approval Of COPIKTR and updates 2018 financial guidance.</li><li><a href='https://seekingalpha.com/symbol/IRDM' title='Iridium Communications Inc'>IRDM</a> <font color='green'>+7%</font>.</li><li><a href='https://seekingalpha.com/symbol/BXE' title='Bellatrix Exploration Ltd'>BXE</a> <font color='green'>+7%.</font></li><li><a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group, Inc.'>CRON</a> <font color='green'>+6%</font>.</li><li><a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation PLC'>AMRN</a> <font color='green'>+5%</font>.</li><li><a href='https://seekingalpha.com/symbol/TRXC' title='TransEnterix, Inc.'>TRXC</a> <font color='green'>+5%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/news/3393971-transenterix-receives-ce-mark-approval-senhance-ultrasonic-instrument-system\" target=\"_blank\">receiving</a>&nbsp;CE mark approval for senhance ultrasonic instrument system.</li></ul><div class=\"tiny-share-widget\" data-id=\"3394030\" data-linked=\"Premarket Gainers as of 9:05 am (10/01/2018)\" data-tweet=\"$SYN $SYN $NBEV - Premarket Gainers as of 9:05 am (10/01/2018) https://seekingalpha.com/news/3394030-premarket-gainers-of-9-05-10-01-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3394030-premarket-gainers-of-9-05-10-01-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394027\" data-ts=\"1538400264\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INFI\" target=\"_blank\">INFI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394027-infinity-pharma-up-7-premarket-on-22m-milestone-from-verastem\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Infinity Pharma up 7% premarket on $22M milestone from Verastem</a></h4><ul><li>Thinly traded micro cap Infinity Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/INFI' title='Infinity Pharmaceuticals, Inc.'>INFI</a>) is up&nbsp;<font color='green'>7%</font>&nbsp;premarket on light volume following its <a href=\"https://seekingalpha.com/pr/17285937-infinity-pharmaceuticals-earns-22-million-payment-verastem-oncology-fda-approval-copiktra\" target=\"_blank\">announcement </a>that it has earned a $22M milestone payment from Verastem Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/VSTM' title='Verastem, Inc.'>VSTM</a>) triggered by the FDA nod for COPIKTRA (duvelisib). It expects to receive the cash payment later this year.</li><li>The company out-licensed duvelisib to Verastem in 2016.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3392533-fda-oks-verastems-duvelisib-shares-3-percent-trade-halt\" target=\"_blank\">FDA OKs Verastem's duvelisib; shares up 3% before trade halt</a> (Sept. 24)</li></ul><div class=\"tiny-share-widget\" data-id=\"3394027\" data-linked=\"Infinity Pharma up 7% premarket on $22M milestone from Verastem\" data-tweet=\"$INFI $INFI $VSTM - Infinity Pharma up 7% premarket on $22M milestone from Verastem https://seekingalpha.com/news/3394027-infinity-pharma-up-7-premarket-on-22m-milestone-from-verastem?source=tweet\" data-url=\"https://seekingalpha.com/news/3394027-infinity-pharma-up-7-premarket-on-22m-milestone-from-verastem\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394020\" data-ts=\"1538399672\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VERU\" target=\"_blank\">VERU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394020-veru-enrolls-first-patient-in-phase-2-study-of-zuclomiphene-citrate-for-treatment-of-hot\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Veru enrolls first patient in Phase 2 study of zuclomiphene citrate for the treatment of hot flashes caused by ADT</a></h4><ul> <li>Veru Inc. (NASDAQ:<a href='https://seekingalpha.com/symbol/VERU' title='Veru Inc.'>VERU</a>) <a href=\"https://seekingalpha.com/pr/17285587-first-patient-enrolled-phase-2-study-zuclomiphene-citrate-treatment-hot-flashes-caused\" target=\"_blank\">enrolls</a> the first patient in its Phase 2 study of zuclomiphene citrate for the treatment of hot flashes caused by androgen deprivation therapy &#40;ADT&#41; for men with advanced prostate cancer.</li><li>The study,&nbsp;is designed to enroll ~ 120 patients randomized to one of four treatment arms (zuclomiphene 10 mg, 50 mg,100 mg, or placebo). The primary endpoint of the study is the mean change in frequency and severity of hot flashes relative to baseline at week 4.</li>   <li>Top-line results are expected in H1 2019.</li><li>Shares are up&nbsp;<font color='green'>5%</font>&nbsp;premarket.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3394020\" data-linked=\"Veru enrolls first patient in Phase 2 study of zuclomiphene citrate for the treatment of hot flashes caused by ADT\" data-tweet=\"$VERU - Veru enrolls first patient in Phase 2 study of zuclomiphene citrate for the treatment of hot flashes caused by ADT https://seekingalpha.com/news/3394020-veru-enrolls-first-patient-in-phase-2-study-of-zuclomiphene-citrate-for-treatment-of-hot?source=tweet\" data-url=\"https://seekingalpha.com/news/3394020-veru-enrolls-first-patient-in-phase-2-study-of-zuclomiphene-citrate-for-treatment-of-hot\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394017\" data-ts=\"1538399338\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMAT\" target=\"_blank\">AMAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394017-deutsche-and-mizuho-throw-in-towel-on-semi-nand-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deutsche and Mizuho throw in towel on semi, NAND stocks</a></h4><ul><li>Deutsche Bank downgrades Applied Materials (NASDAQ:<a href='https://seekingalpha.com/symbol/AMAT' title='Applied Materials, Inc.'>AMAT</a>) from Buy to Hold and cuts the target from $58 to $43, an 11% upside to Friday&rsquo;s close.</li><li>The firm also downgrades Lam Research (NASDAQ:<a href='https://seekingalpha.com/symbol/LRCX' title='Lam Research Corporation'>LRCX</a>) from Buy to Hold and drops the target from $230 to $170, a 12% upside.</li><li>Deutsche sees a \"lack of potential catalysts\" and capex push-out uncertainties.</li><li>More action: Mizuho Securities downgrades Lam Research from Buy to Neutral and cuts its target from $165 to $225.</li><li>        Update:&nbsp;Mizuho downgrades Western Digital (NYSE:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>) from Buy to Neutral with the target dropping from $100 to $65, an 11% upside to Friday&rsquo;s close.</li><li>               Analyst Vijay Rakesh cites the firm&rsquo;s recent Asia Tour for expectations of further downsides to NAND ASPs over the next year. This forecast motivated the downgrades of WDC&nbsp;and Lam Research.</li><li>               Western Digital shares are<font color='red'> down 0.9%</font>&nbsp;premarket to $58.01.&nbsp;&nbsp;</li><li>Sources: StreetAccount / Bloomberg First Word.</li><li>Note: Post and title edited to incorporate the additional information.&nbsp;&nbsp;</li><li>NAND players and semi equipment stocks could move today on these downgrades and the Intel/AMD reductions from earlier.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3393958-intel-amd-drop-analysts-cut-expectations\" target=\"_blank\">Intel, AMD drop as analysts cut expectations</a> (Oct. 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3394017\" data-linked=\"Deutsche and Mizuho throw in towel on semi, NAND stocks\" data-tweet=\"$AMAT $AMAT $LRCX - Deutsche and Mizuho throw in towel on semi, NAND stocks https://seekingalpha.com/news/3394017-deutsche-and-mizuho-throw-in-towel-on-semi-nand-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3394017-deutsche-and-mizuho-throw-in-towel-on-semi-nand-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394016\" data-ts=\"1538399319\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PHIO\" target=\"_blank\">PHIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394016-premarket-losers-of-9-05-10-1-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am (10/1/2018)</a></h4><ul><li>RXII&nbsp;<font color='red'>-49%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3393940-rxi-pharmaceuticals-49-percent-pricing-15m-public-offering\" target=\"_blank\">pricing</a> $15M public offering.</li><li><a href='https://seekingalpha.com/symbol/INFN' title='Infinera Corporation'>INFN</a>&nbsp;<font color='red'>-14%</font>&nbsp;as analyst <a href=\"https://seekingalpha.com/news/3393966-infinera-minus-13_7-percent-analyst-predicts-major-customer-loss\" target=\"_blank\">predicts</a> major customer loss.</li><li><a href='https://seekingalpha.com/symbol/UEC' title='Uranium Energy Corp'>UEC</a> <font color='red'>-10%</font>.</li><li><a href='https://seekingalpha.com/symbol/GERN' title='Geron Corporation'>GERN</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3394016\" data-linked=\"Premarket Losers as of 9:05 am (10/1/2018)\" data-tweet=\"$PHIO $PHIO $INFN - Premarket Losers as of 9:05 am (10/1/2018) https://seekingalpha.com/news/3394016-premarket-losers-of-9-05-10-1-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3394016-premarket-losers-of-9-05-10-1-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394014\" data-ts=\"1538399154\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394014-netflix-content-expected-to-dazzle-in-2019\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Netflix content expected to dazzle in 2019</a></h4><ul> <li>Credit Suisse previews how the 2019 content slate is looking for Netflix (NASDAQ:<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a>).</li> <li>The firm says 2019 content is shaping up to be \"meaningfully stronger\" than 2018 in a development that bodes well for subscriber growth, both domestic and globally.</li> <li>CS notes that promising movies include Martin Scorsese's <em>The Irishman</em> and Michael Bay's <em>Six Underground</em>. New series include <em>The Witcher</em> and the beginning of Shonda Rhimes&rsquo; contributions.</li> <li>\"The service is not solely hit-driven; the slate is deeper with more dramas, movies and international content, driven by more internally produced content,\" notes CS.</li> <li>Returning series includes <em>Stranger Things, Black Mirror, Star Trek Discovery (International only), The Crown, Mindhunter, Dark, Money Heist, Suburra, Fuller House, Club de Cuervos, Bright</em> and a follow up to <em>Making A Murderer</em>.</li><li>Add it all up and Credit Suisse has an Outperform rating on Netflix and price target of $470 (+25% upside potential).</li><li>NFLX&nbsp;<font color='green'>+1.05%</font>&nbsp;premarket to $378.26 vs. a 52-week trading range of $176.58 to $423.31.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3394014\" data-linked=\"Netflix content expected to dazzle in 2019\" data-tweet=\"$NFLX - Netflix content expected to dazzle in 2019 https://seekingalpha.com/news/3394014-netflix-content-expected-to-dazzle-in-2019?source=tweet\" data-url=\"https://seekingalpha.com/news/3394014-netflix-content-expected-to-dazzle-in-2019\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394011\" data-ts=\"1538399065\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADMA\" target=\"_blank\">ADMA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394011-adma-biologics-resubmits-bla-for-riminus-002\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ADMA Biologics resubmits BLA for RI-002</a></h4><ul> <li>ADMA Biologics (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMA' title='ADMA Biologics Inc'>ADMA</a>) has <a href=\"https://seekingalpha.com/pr/17285575-adma-biologics-resubmits-biologics-license-application-riminus-002\" target=\"_blank\">responded</a> to the July 2016 Complete Response Letter (&ldquo;CRL&rdquo;) and resubmitted its Biologics License Application (&ldquo;BLA&rdquo;) for RI-002 to the FDA on September 28, 2018.</li>   <li>The Company was able to resubmit RI-002&rsquo;s BLA as a direct result of the recent improvement in compliance status for the Company&rsquo;s Boca Raton, FL manufacturing facility to Voluntary Action Indicated (&ldquo;VAI&rdquo;), as previously announced in September 2018.</li>    <li>The FDA typically provides companies with a notification of BLA acceptance within 60 days of submission, and ADMA anticipates that the agency will set a PDUFA target action date for RI-002 at that time.</li><li>Shares are up&nbsp;<font color='green'>2%</font>&nbsp;premarket.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3394011\" data-linked=\"ADMA Biologics resubmits BLA for RI-002\" data-tweet=\"$ADMA - ADMA Biologics resubmits BLA for RI-002 https://seekingalpha.com/news/3394011-adma-biologics-resubmits-bla-for-riminus-002?source=tweet\" data-url=\"https://seekingalpha.com/news/3394011-adma-biologics-resubmits-bla-for-riminus-002\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394012\" data-ts=\"1538399061\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVRO\" target=\"_blank\">AVRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394012-avrobio-down-15-premarket-following-announcement-of-trial-data-on-fabry-gene-therapy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AVROBIO down 15% premarket following announcement of trial data on Fabry gene therapy</a></h4><ul><li>Thinly traded AVROBIO (NASDAQ:<a href='https://seekingalpha.com/symbol/AVRO' title='AVROBIO'>AVRO</a>) slumps&nbsp;<font color='red'>15%</font>&nbsp;premarket on light volume in apparent reaction to <a href=\"https://seekingalpha.com/pr/17285539-avrobio-announces-updated-clinical-data-avr-rdminus-01-gene-therapy-fabry-disease\" target=\"_blank\">updated Phase 1 data</a> on gene therapy AVR-RD-01 in patients with Fabry disease.</li><li>Results from the first two treated participants in the six-subject open-label single-arm study showed \"AGA enzyme activity above the diagnostic range\" for classic Fabry 18 months and six months, respectively, after a single administration of AVR-RD-01. Patient #1 was taken off enzyme replacement therapy.</li><li>The first dosed patient in a Phase 2 study experienced a significant increase in AGA enzyme activity at month 3 post-treatment.</li><li>Separately, the company is <a href=\"https://seekingalpha.com/pr/17285566-avrobio-receives-objection-clinical-trial-application-health-canada-avr-rdminus-02-gene\" target=\"_blank\">on go to start</a> a Phase 1/2 study in Canada evaluating gene therapy AVR-RD-02 in Gaucher.</li></ul><div class=\"tiny-share-widget\" data-id=\"3394012\" data-linked=\"AVROBIO down 15% premarket following announcement of trial data on Fabry gene therapy\" data-tweet=\"$AVRO - AVROBIO down 15% premarket following announcement of trial data on Fabry gene therapy https://seekingalpha.com/news/3394012-avrobio-down-15-premarket-following-announcement-of-trial-data-on-fabry-gene-therapy?source=tweet\" data-url=\"https://seekingalpha.com/news/3394012-avrobio-down-15-premarket-following-announcement-of-trial-data-on-fabry-gene-therapy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393984\" data-ts=\"1538398136\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTGN\" target=\"_blank\">NTGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393984-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Neon Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NTGN' title='Neon Therapeutics'>NTGN</a>) initiated with Buy rating and $20 (134% upside) price target at Ladenburg Thalmann.</li><li>Incyte (NASDAQ:<a href='https://seekingalpha.com/symbol/INCY' title='Incyte Corporation'>INCY</a>) initiated with Neutral rating and $73 (6% upside) price target at Cantor Fitzgerald.</li><li>Intercept Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ICPT' title='Intercept Pharmaceuticals'>ICPT</a>) resumed with Overweight rating and $170 (35% upside) price target at Cantor. Shares up&nbsp;<font color='green'>1%&nbsp;</font>premarket.</li><li>Celgene (NASDAQ:<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a>) initiated with Overweight rating and $100 (16% upside) price target at Cantor. Shares up&nbsp;<font color='green'>1%</font>&nbsp;premarket.</li><li>BioMarin Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/BMRN' title='BioMarin Pharmaceutical Inc.'>BMRN</a>) initiated with Overweight rating and $126 (30% upside) price target at Cantor.</li><li>PTC Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTCT' title='PTC Therapeutics'>PTCT</a>) initiated with Overweight rating and $66 (40% upside) price target at Cantor.</li><li>Puma Biotechnology (NYSE:<a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a>) initiated with Overweight rating and $75 (63% upside) price target at Cantor.</li><li>Regeneron Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a>) initiated with Neutral rating and $415 (3% upside) price target at Cantor. Shares up<font color='green'> 2%</font>&nbsp;premarket.</li><li>TESARO (NASDAQ:<a href='https://seekingalpha.com/symbol/TSRO' title='Tesaro'>TSRO</a>) initiated with Overweight rating and $57 (46% upside) price target at Cantor. Shares up&nbsp;<font color='green'>1%</font>&nbsp;premarket.</li><li>Vertex Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a>) initiated with Overweight rating and $217 (12% upside) price target at Cantor.</li><li>Sarepta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a>) initiated with Overweight rating and $217 (34% upside) price target at Cantor. Shares up&nbsp;<font color='green'>1%&nbsp;</font>premarket.</li><li>Biogen (NASDAQ:<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a>) resumed with Overweight rating and $400 (13% upside) price target at Cantor.</li><li>Amgen (NASDAQ:<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a>) initiated with Neutral rating and $223 (8% upside) price target at Cantor. Shares up a fraction premarket.</li><li>MyoKardia (NASDAQ:<a href='https://seekingalpha.com/symbol/MYOK' title='MyoKardia'>MYOK</a>) initiated with Overweight rating and $90 (38% upside) price target at Cantor. Shares up&nbsp;<font color='green'>4%</font>&nbsp;premarket.</li><li>Alnylam Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a>) initiated with Overweight rating and $135 (54% upside) price target at Cantor.</li><li>Teva Pharmaceutical Industries (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) added to Conviction Buy List at Goldman Sachs. Shares up&nbsp;<font color='green'>3%</font>&nbsp;premarket.</li><li>Teva upgraded to Market Perform at Leerink Partners.</li></ul><div class=\"tiny-share-widget\" data-id=\"3393984\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$NTGN $NTGN $INCY - Premarket analyst action - healthcare https://seekingalpha.com/news/3393984-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3393984-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394002\" data-ts=\"1538398040\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLRY\" target=\"_blank\">TLRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394002-tilray-subsidiary-high-park-farms-receives-cannabis-sales-license-from-health-canada\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tilray subsidiary High Park Farms receives cannabis sales license from Health Canada</a></h4><ul> <li>High Park Farms Ltd.,&nbsp;a subsidiary of Tilray, (NASDAQ:<a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a>) has <a href=\"https://seekingalpha.com/pr/17285413-high-park-farms-receives-cannabis-sales-license-health-canada\" target=\"_blank\">received</a> its sales license from Health       Canada to sell cannabis under the Access to Cannabis for Medical       Purposes Regulations &#40;ACMPR&#41;.</li><li>The license will allow High Park Farms to       supply and sell finished cannabis products within the ACMPR as well as       sales in anticipation of the launch of the adult-use market in Canada       upon its legalization on October 17.</li>          <li>The       state-of-the-art High Park Farms facility features 13 acres of       greenhouse space on 100 acres of property in Enniskillen, Ontario. Going       forward, High Park intends to primarily serve the adult-use market in       Canada, while medical cannabis production will continue to take place at       the headquarters of its affiliate, Tilray Canada Ltd., in Nanaimo, BC.</li><li>Shares of TLRY are up&nbsp;<font color='green'>8%</font>&nbsp;premarket.</li>          </ul><div class=\"tiny-share-widget\" data-id=\"3394002\" data-linked=\"Tilray subsidiary High Park Farms receives cannabis sales license from Health Canada\" data-tweet=\"$TLRY - Tilray subsidiary High Park Farms receives cannabis sales license from Health Canada https://seekingalpha.com/news/3394002-tilray-subsidiary-high-park-farms-receives-cannabis-sales-license-from-health-canada?source=tweet\" data-url=\"https://seekingalpha.com/news/3394002-tilray-subsidiary-high-park-farms-receives-cannabis-sales-license-from-health-canada\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394001\" data-ts=\"1538397983\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHEF\" target=\"_blank\">CHEF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394001-chefs-warehouse-lower-after-bmo-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chefs&#39; Warehouse lower after BMO downgrade</a></h4><ul> <li>Chefs' Warehouse (NASDAQ:<a href='https://seekingalpha.com/symbol/CHEF' title='Chefs&#39; Warehouse'>CHEF</a>) falls sharply in premarket action (light volume) after BMO Capital drops its rating to Market Perform from Outperform.</li> <li>Analyst Kelly Bania sets a price target on the restaurant industry supplier of $38. The 52-week for Chefs' is $38.20.</li> <li>CHEF <font color='red'>-3.51%</font> premarket to $35.00.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3394001\" data-linked=\"Chefs&#39; Warehouse lower after BMO downgrade\" data-tweet=\"$CHEF - Chefs&#39; Warehouse lower after BMO downgrade https://seekingalpha.com/news/3394001-chefs-warehouse-lower-after-bmo-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3394001-chefs-warehouse-lower-after-bmo-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3394000\" data-ts=\"1538397919\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROKU\" target=\"_blank\">ROKU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3394000-roku-gains-on-target-boost-to-16-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Roku gains on target boost to 16% upside</a></h4><ul><li>        Needham maintains a Buy rating on Roku (NASDAQ:<a href='https://seekingalpha.com/symbol/ROKU' title='Roku Inc.'>ROKU</a>) and ups its price target from $60 to $85, a 16% upside to Friday&rsquo;s close.</li><li>                  Analyst Laura Martin sees additional upsides despite the recent outperformance, citing the superb execution, potential TAM expansion, platform ad revenue growth, and reduced competitive threats.&nbsp;    </li><li>               Source: StreetAccount.&nbsp;</li><li>                  Roku shares are&nbsp;<font color='green'>up 1.6%&nbsp;</font>premarket to $74.20.&nbsp;    &nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3394000\" data-linked=\"Roku gains on target boost to 16% upside\" data-tweet=\"$ROKU - Roku gains on target boost to 16% upside https://seekingalpha.com/news/3394000-roku-gains-on-target-boost-to-16-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3394000-roku-gains-on-target-boost-to-16-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393997\" data-ts=\"1538397515\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FFIV\" target=\"_blank\">FFIV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393997-f5-networksminus-2_7-analyst-warns-of-near-term-earnings-risk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">F5 Networks -2.7% as analyst warns of near-term earnings risk</a></h4><ul><li>        Piper Jaffray downgrades F5 Networks (NASDAQ:<a href='https://seekingalpha.com/symbol/FFIV' title='F5 Networks, Inc.'>FFIV</a>) from Neutral to Underweight but increases the price target from $168 to $180.</li><li>               The firm sees near-term risk to earnings due to softer demand trends and competitive pressures. F5 reports Q4 results on October 24.&nbsp;</li><li>               Analyst James Fish cites an unattractive risk/reward balance with the stock trading at a peak valuation multiple.&nbsp;</li><li>               Source: StreetAccount. &nbsp;&nbsp;</li><li>                  F5 shares are&nbsp;<font color='red'>down 2.7%</font>&nbsp;premarket to $194.01.&nbsp;&nbsp;&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3393997\" data-linked=\"F5 Networks -2.7% as analyst warns of near-term earnings risk\" data-tweet=\"$FFIV - F5 Networks -2.7% as analyst warns of near-term earnings risk https://seekingalpha.com/news/3393997-f5-networksminus-2_7-analyst-warns-of-near-term-earnings-risk?source=tweet\" data-url=\"https://seekingalpha.com/news/3393997-f5-networksminus-2_7-analyst-warns-of-near-term-earnings-risk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3393992\" data-ts=\"1538397134\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PX\" target=\"_blank\">PX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3393992-praxair-linde-merger-deal-receives-approval-from-china\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Praxair-Linde merger deal receives approval from China</a></h4><ul>     <li>Praxair (NYSE:<a href='https://seekingalpha.com/symbol/PX' title='Praxair, Inc.'>PX</a>)&nbsp;<font color='green'>+2.7%</font> pre-market after merger partner Linde (<a href='https://seekingalpha.com/symbol/LNAGF' title='Linde AG'>OTCPK:LNAGF</a>) says it <a href=\"https://www.reuters.com/article/us-linde-m-a-praxair/chinese-regulator-signs-off-on-linde-praxair-merger-idUSKCN1MA0E8\" target=\"_blank\">received approval</a> for the proposed deal from Chinese regulators.</li>     <li>The companies are in the process of <a href=\"https://seekingalpha.com/news/3391382-report-praxair-linde-nearing-additional-asset-sales-save-merger\" target=\"_blank\">selling additional assets</a> in an attempt to win approval for the tie-up by an Oct. 24 deadline from regulators in the U.S., South Korea and the European Union; the deal was approved by Brazilian authorities a few weeks ago.</li></ul><div class=\"tiny-share-widget\" data-id=\"3393992\" data-linked=\"Praxair-Linde merger deal receives approval from China\" data-tweet=\"$PX $PX $LNAGF - Praxair-Linde merger deal receives approval from China https://seekingalpha.com/news/3393992-praxair-linde-merger-deal-receives-approval-from-china?source=tweet\" data-url=\"https://seekingalpha.com/news/3393992-praxair-linde-merger-deal-receives-approval-from-china\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}